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Summary 
 
The probiotic Escherichia coli strain Nissle 1917 (EcN) is one of the few 
probiotics licensed as a medication in several countries. Best documented is its 
effectiveness in keeping patients suffering from ulcerative colitis (UC) in remission. 
This might be due to its ability to induce the production of human beta defensin 2 
(HBD2) in a flagellin-dependent way in intestinal epithelial cells. In contrast to 
ulcerative colitis, for Crohn´s disease (CD) convincing evidence is lacking that EcN 
might be clinically effective, most likely due to the genetically based inability of 
sufficient defensin production in CD patients. 
As a first step in the development of an alternative approach for the treatment 
of CD patients, EcN strains were constructed which were able to produce human 
alpha-defensin 5 (HD5) or beta-defensin 2 (HBD2). For that purpose codon-optimized 
defensin genes encoding either the proform with the signal sequence or the mature 
form of human alpha defensin 5 (HD5) or the gene encoding HBD2 with or without 
the signal sequence were cloned in an expression vector plasmid under the control of 
the T7 promoter. Synthesis of the encoded defensins was shown by Western blots 
after induction of expression and lysis of the recombinant EcN strains. Recombinant 
mature HBD2 with an N-terminal His-tag could be purified by Ni-column 
chromatography and showed antimicrobial activity against E. coli, Salmonella 
enterica serovar Typhimurium and Listeria monocytogenes. In a second approach, 
that part of the HBD2-gene which encodes mature HBD2 was fused with yebF gene. 
The resulting fusion protein YebFMHBD2 was secreted from the encoding EcN 
mutant strain after induction of expression. Presence of YebFMHBD2 in the medium 
was not the result of leakage from the bacterial cells, as demonstrated in the spent 
culture supernatant by Western blots specific for ß-galactosidase and maltose-
binding protein. The dialyzed and concentrated culture supernatant inhibited the 
growth of E. coli, Salmonella enterica serovar Typhimurium and Listeria 
monocytogenes in radial diffusion assays as well as in liquid coculture. This 
demonstrates EcN to be a suitable probiotic E. coli strain for the production of certain 
defensins.  
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Zusammenfassung 
 
Der probiotische Escherichia coli Stamm Nissle 1917 (EcN) ist eines der wenigen 
Probiotika, die als aktive Komponente eines Medikaments in mehreren Ländern 
zugelassen sind. Am besten ist die Wirksamkeit des EcN für die 
Remissionserhaltung von an Colitis Ulcerosa leidenden Patienten dokumentiert. 
Diese Fähigkeit ist vermutlich darauf zurückzuführen, dass EcN in der Lage ist die 
Produktion des humanen beta-Defensins 2 (HBD2) mittels seiner Flagelle zu 
Induzieren. In dieser Studie wurden rekombinante EcN Stämme konstruiert, die ein 
Defensin zu produzieren vermögen. Zu diesem Zweck wurden Kodon-optimierte 
Defensingene in Expressionsplasmidvektoren kloniert, die entweder die Proform mit 
der Signalsequenz oder die reife Defensinform des humanen -Defensins 5 (HD5) 
oder des humanen -Defensins 2 (HBD2) unter der Kontrolle des T7-Promotors 
kodieren. Die Synthese dieser Defensine wurde mittels Western-Blot nach der 
Induktion der Expression und der Lyse der rekombinanten EcN Stämme demonstriert. 
Das rekombinante reife HBD2 mit einem N-terminalen His-Tag konnte mittels Ni-
Säulen-Chromatographie aufgereinigt werden. Das so gewonnene HBD2 zeigte 
antimikrobielle Aktivität gegen E. coli, Salmonella enterica Serovar Typhimurium und 
Listeria monocytogenes. In einem zweiten Ansatz wurde der Teil des HBD2-Gens mit 
dem yebF-Gen fusioniert, der das reife HBD2 kodiert. Das resultierende 
Fusionsprotein YebFMHBD2 wurde von dem entsprechenden EcN Stamm nach 
Induktion der Expression sekretiert. Die Präsenz von YebFMHBD2 im Medium war 
nicht das Ergebnis von Zellyse wie Western-Blots spezifisch für die -Galaktosidase 
und das Maltose-Bindeprotein mit dem Kulturüberstand zeigten. Dieser 
Kulturüberstand inhibierte das Wachstum von E. coli, Salmonella enterica Serovar 
Typhimurium und Listeria monocytogenes nach Dialyse und Aufkonzentration sowohl 
in Agardiffusionsassays als auch in Flüssigcokultur. Damit konnte gezeigt werden, 
dass EcN ein für die Produktion von bestimmten humanen Defensinen geeignetes 
Probiotikum darstellt.  
EcN ist bei der Behandlung von Morbus Crohn Patienten nicht aktiv. Dies ist 
vermutlich in der genetisch bedingten Unfähigkeit zur ausreichenden 
Defensinproduktion solcher Individuen begründet. Als ein erster Schritt in der 
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Entwicklung von alternativen Ansätzen zur Behandlung Morbus Crohn Patienten 
wurden in dieser Arbeit EcN Stämme konstruiert, die in der Lage sind HD5 oder 
HBD2 zu produzieren.  
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1. Introduction 
 
1.1. Probiotic Escherichia coli strain Nissle 1917 (EcN)  
1.1.1. Probiotics 
Probiotics are by definition living non-pathogenic micro-organisms, which exert 
a positive effect on the host organisms when they get into the gastrointestinal tract in 
a viable condition in sufficiently large numbers (Food and Agriculture Organization of 
the United Nations. and World Health Organization. 2006). Probiotic microorganisms 
are often found as food ingredients, e.g. in fermented milk products and food 
supplements, but are also employed as feed additives in livestock breeding and as 
active components of medical remedies in human and veterinary medicine (Bansal 
and Garg 2008, Bengmark 2005, de Vrese and Schrezenmeir 2008, Marteau 2006). 
Usually in the food industry, probiotics mostly are lactic acid bacteria (LAB), such as 
lactobacilli, lactococci, bifidobacteria and streptococci (enterococci) (Gill and Prasad 
2008). However, other non-pathogenic microorganisms, e.g. certain yeast strains 
(Saccharomyces boulardii) and Escherichia coli strains, like E. coli Nissle 1917 (EcN) 
are also used in human and veterinary medicine (Fric 2002, Hart et al. 2003, 
Heselmans et al. 2005, Reid and Devillard 2004, Schultz 2008).  
 
1.1.2. E. coli Nissle 1917 (EcN) 
The requirements to be met by a probiotic intended for medical application are 
demanding: proof is required of clinical efficacy in defined medical indications, 
evidence of effects and mechanisms of action, and compliance with specific criteria 
relating to product quality including non-pathogenicity and genetic stability of the 
micro-organism used therapeutically.  
All the criteria for a probiotic medicine are fulfilled completely by E. coli Nissle 
1917 (EcN), the active substance of Mutaflor® (Ardeypharm GmbH, Herdecke, 
Germany), which is used for treatment of various intestinal disorders and is known to 
be a successful colonizer of the human gut (Boudeau et al. 2003, Lodinova-
Zadnikova and Sonnenborn 1997, Rembacken et al. 1999, Sonnenborn and Schulze 
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2009). This strain was originally isolated by Alfred Nissle in 1917 from a soldier who 
was not affected, in contrast to his comrades, by a severe outbreak of diarrhea 
(Blum-Oehler et al. 2003). 
 
1.1.2.1. General properties of EcN 
E. coli Nissle 1917 has been thoroughly analyzed by means of microbiological, 
biochemical and molecular genetic methods (Blum-Oehler et al. 2003, Blum et al. 
1995, Grozdanov et al. 2004, Grozdanov et al. 2002). The strain does not exhibit any 
virulence factors, but has gene clusters located on genomic islands (GEIs) 
responsible for the synthesis of several so-called `fitness factors´, which contribute to 
the strain's probiotic nature. Serologically, EcN belongs to the E. coli O6 group and is 
of serotype O6:K5:H1 (Blum et al. 1995, Grozdanov et al. 2002). EcN is a typical 
gram-negative enterobacterium containing lipopolysaccharide (LPS) as a structural 
component of its outer cell membrane. The O6 surface antigen represents the outer 
part of the strain's LPS and exhibits some peculiar features. The O6 polysaccharide 
side-chain is very short, consisting of only one single `repeating unit´ of the 
oligosaccharide building block typical of the O6 antigen, giving the strain a so-called 
`semi-rough´ phenotypic appearance. EcN is able to form an extracellular capsule of 
the K5 serotype. This kind of capsule is present in only about 1 % of E. coli isolates. 
The chromosomal gene locus responsible for the synthesis of the K5 capsule has 
been detected by using a gene probe specific for the K5 capsule gene cluster (Ott et 
al. 1991). EcN possesses flagella of serotype H1 and is thus quite mobile. The 
possession of flagella enables the microbe to actively move within the gut lumen and 
the outer layer of the two layered mucus, which serves as an oxygen source, useful 
for aerobic catabolism of substrates by E. coli. Besides their function as driving 
apparatus, the flagella are important in bacterial crosstalk with the epithelium (Cario 
2005, Wang et al. 2005). EcN possesses three different types of fimbriae: F1A (type 
1) and F1C fimbriae as well as so-called `curli´ fimbriae, which mediate adhesion to 
intestinal epithelial cells in cell culture experiments or to the mucus layer of the 
intestinal wall in vivo, facilitating colonization of the gut (Blum et al. 1995, Grozdanov 
et al. 2004, Hammar et al. 1995, Lasaro et al. 2009, Stentebjerg-Olesen et al. 1999).  
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1.1.2.2. Fitness factors of EcN 
Non-pathogenic (avirulent) commensal bacteria may also produce specific 
factors that enable them to compete with other strains in the ecological system of the 
gut and to effectively communicate with the host organism. These factors are 
designated fitness factors, which are also often encoded by special DNA sequences 
(genomic islands, GEIs) on the bacterial chromosome (Hacker and Carniel 2001, 
Hacker et al. 2003). Different fitness factors have been detected in EcN strain. 
Siderophores are iron-chelating substances needed for bacterial iron uptake. 
EcN produces an unexpectedly wide array of siderophores: aerobactin, enterobactin, 
salmochelin, yersiniabactin as well as a hemin- and a citrate-dependent iron 
acquisition system. Besides the siderophore ferric iron uptake systems, EcN also 
possesses an elemental ferrous iron uptake system (EfeU) (Grosse et al. 2006).  
The antagonistic actions of EcN are due, at least in part, to the formation of 
microcins against which the producer strain itself is immune. One of these microcins 
(microcin H47) had already been described before for another E. coli strain, whereas 
the second microcin was unknown so far. The latter has been termed `microcin M´ (M 
from Mutaflor®) by Klaus Hanke and colleagues (Azpiroz et al. 2001, Gaggero et al. 
1993, Patzer et al. 2003, Rodriguez et al. 1999) (Fig. 1). 
In addition to the production of microcins, EcN belongs to the phylogenetic 
subgroup of E. coli bacteria (group B2) that contains strains able to synthesize 
peptide/polyketide hybrids (Homburg et al. 2007, Nougayrede et al. 2006). These 
substances belong to a heterogeneous group of molecules with antimicrobial and 
antitumor activities. 
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Fig. 1. Fitness factors of EcN, Schematic representation of the major surface structures and other 
factors that contribute to the fitness of the strain (modified from Blum-Oehler et al. 1995). 
 
This probiotic drug, Mutaflor®, is successfully used in several countries for the 
treatment of various diseases of the digestive tract, including acute and prolonged 
diarrhea (Henker et al., 2007; 2008), uncomplicated diverticular disease (Fric and 
Zavoral, 2003), and inflammatory bowel disease (IBD) (Kruis et al. 1997, 2004, 
Matthes et al., 2010, Rembacken et al., 1999). It is particularly used for maintenance 
therapy of remission in patients with ulcerative colitis (UC) (Schultz, 2008). In 
ulcerative colitis, it is thought that one of the main mechanisms of action of EcN is the 
induction of defensin synthesis in intestinal epithelial cells (Wehkamp et al., 2004). 
The molecular mechanism behind the clinical effectiveness of EcN in UC-treatment 
might be the flagellin-mediated enhancement of human beta-defensin 2 (HBD2) 
production which is due to induction of a NF-kB- and AP-1-dependent signaling 
pathway (Schlee et al., 2007). 
Wehkamp and his colleagues showed that the induction of HBD2 by EcN was 
dose-dependent with a maximum of 362-fold at the highest bacterial concentration 
tested in contrast to HBD-1 and HD-6 (Wehkamp et al. 2004a). 
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1.2. Expression of antimicrobial peptides in the gastrointestinal (GI) tract 
1.2.1. Microbial/Host interactions 
The gastrointestinal (GI) tract is unique, as it represents the largest area of the 
body that is constantly exposed to microorganisms. This exposure occurs in 
association with oral intake (which may be contaminated with microorganisms) and 
the resident microbial flora, varying in distinct proximal to distal regions of the GI tract. 
Of the resident flora in the oral cavity, Streptococci predominate. In the stomach, 
although the secreted gastric acid aims to keep the lumen largely sterile, 
Helicobacter pylori are resident in the mucus layer of many individuals. The proximal 
small intestine (duodenum, jejunum, proximal ileum), which mediates the important 
functions of digestion and absorption of nutrients, is colonized by small numbers of 
bacteria (102-103). In the distal ileum and the colon, there is an extensive resident 
bacterial flora (total ~1014) consisting of ~400 different species of anaerobic and 
aerobic bacteria (Heneghan 1965, Sartor 2008). 
Gastric and other secretions, motility, and secretory immunoglobulin A (a 
composition of mucosal adaptive immunity) have been known for many years to 
provide protection against microorganisms in the GI tract. In recent years, there has 
been increasing appreciation of the likely importance of antimicrobial peptides and 
proteins as components of innate immunity against microorganisms. The 
antimicrobial peptides/proteins are expressed predominantly by epithelial cells, which 
have distinct characteristics in different regions of the GI tract. 
Numerous factors may regulate the expression of antimicrobial peptides in the 
GI tract. These include intra- and extra- cellular processing of biologically inactive 
precursor forms of a peptide, epithelial interactions with pathogenic and resident 
inflammation (e.g. inflammatory bowel disease). Additional factors include the type 
and number of antimicrobial peptide expressing epithelial cells and their state of 
differentiation. In inflamed tissue, there is infiltration from the circulation by 
antimicrobial peptide/protein expressing polymorphonulcear leukocytes, which 
contribute to innate mucosal host defense (Cunliffe and Mahida 2004).  
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1.2.2. Intestinal epithelial cells and the expression and regulation of 
antimicrobial peptides 
In the small intestine, there are four main epithelial cell types: absorptive cells, 
goblet cells, enteroendocrine cells and Paneth cells, which are derived from 
multipotent stem cells (Booth and Potten 2000, Cheng and Leblond 1974). Following 
their origin from stem cells present near the crypt base, the epithelial cells (apart from 
Paneth cells) differentiate as they migrate up to the villus tip. They are subsequently 
lost into the lumen via exfoliation and/or apoptosis, which not only facilitates the 
removal of adherent bacteria but is also associated with the release of antimicrobial 
activity (Rose et al. 1998). Paneth cells have generated considerable interest as 
mediators of innate immunity in the GI tract, as they express a number of 
antimicrobial peptides and proteins (Ouellette 1997). In addition to the antimicrobial 
proteins lysozyme and secretory phospholipase A2 (PLA2), Paneth cells have also 
been shown to express members of the α-defensin family in humans (Ghosh et al. 
2002, Jones and Bevins 1992, 1993, Mason and Taylor 1975, Ouellette 1997, Porter 
et al. 1998, Selsted et al. 1992). Paneth cells are restricted to the small intestine, 
where they may play an important role in maintaining the relatively low number of 
bacteria of the lumen and/or provide protection to stem cells (which are located close 
to Paneth cells) in the crypt (Ouellette and Bevins 2001). Cells with morphological 
features of Paneth and goblet cells, designated intermediate cells have been shown 
to express α-defensins by Cunliffe and his colleagues (Cunliffe et al. 2001). 
In contrast to enteric α-defensins, human β-defensin 1 (HBD1), a member of 
the β-defensin family, appears to be expressed by most epithelial cells of the small 
and large intestine (O'Neil et al. 1999). Only during inflammation or infection is the 
synthesis of additional defensins and other antimicrobial peptides by the colonic 
mucosa induced. The inducible antibacterial peptides including HBD2-4, LL37 and 
bactericidal/permeability increasing protein may prevent further bacterial entry into an 
already compromised epithelium and contribute to antimicrobial defense during 
inflammation at this site. The inducible β-defensins are regulated by NF-kB, a 
transcription factor also regulating many proinflammatory cytokines (O'Neil et al. 
1999). Human cathelicidin LL-37/human cationic antimicrobial protein 18 is 
expressed by mature enterocytes in the intestine, but its expression is absent in 
crypts (Hase et al. 2002, Schauber et al. 2003). Bactericidal/permeability increasing 
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protein, an antibacterial and endotoxin-neutralizing protein known to be produced by 
neutrophils, has recently been shown to be expressed by colonic epithelial cells, 
predominantly in the crypt and surface epithelial cells with reduced expression in 
cells in the intermediate zone (Canny et al. 2002). 
 
1.2.3. Antimicrobial peptides 
Antimicrobial peptides are small cationic peptides which protect their hosts 
against a vast array of microorganisms. These peptides are produced by several 
species including bacteria, insects, plants, vertebrates and they have been 
recognized as ancient evolutionary molecules that have been effectively preserved in 
mammals (Lehrer and Ganz 1999). 
Based on their amino acid composition, size and conformational structures, 
antimicrobial peptides are divided into several categories such as peptides with linear 
α-helix structures, like human cathelicidin; peptides with β-sheet structures stabilized 
by disulfide bridges, like human defensins; peptides with extended structures, like 
indolicidin a bovine antimicrobial peptide; and peptides with loop structures, like 
cyclic defensins found in rhesus macaques (Lai and Gallo 2009). 
Antimicrobial peptides are expressed on the primary barriers of organism such 
as skin and mucosal epithelia, preventing the colonization of host tissues by 
pathogens (Bulet et al. 2004). Moreover, these peptides are stored in granules within 
phagocytes, where they assist in the killing of engulfed microorganisms (Ganz 1999, 
Zasloff 2002). 
 
1.2.3.1. Defensins 
Defensins are antimicrobial peptides secreted by various cells as a component 
of the innate host defense and they are cationic, arginine-rich, small peptides 
between 3.5 and 4 kDa in size with six cysteines that form three disulfide bridges 
(Ganz and Lehrer 1994, Lehrer et al. 1993, Martin et al. 1995, Wehkamp et al. 
2007a). They exhibit a broad spectrum antimicrobial activity against bacteria, fungi 
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and some enveloped viruses and can also act as chemokines (Chertov et al. 1996, 
Yang et al. 1999).   
 
1.2.3.1.1. The mechanism of defensins 
Permeabilization of target membranes is the crucial step in defensin mediated 
antimicrobial activity and cytotoxicity. Lehrer and his colleagues observed that 
Escherichia coli ML-35 that were treated by defensins became permeable to small 
molecules (Lehrer et al. 1989). The mechanism of action was found as attachment of 
the cationic defensins to the negatively charged bacterial cell surface resulting in a 
membranolytic disruption of the plasma membrane (Ganz 2003, Harder et al. 2001, 
Kagan et al. 1990, Shimoda et al. 1995). Defensins were more active against 
vesicles that included negatively charged phospholipid. In general, the activity of 
defensins against vesicles was diminished in the presence of increased salt 
concentrations, supporting the importance of electrostatic forces between the anionic 
phospholipid headgroups and cationic defensins. This antimicrobial quality allows 
defensins to protect the host epithelium and stem cells from virulent pathogens and 
also help to regulate the number and composition of commensal microbiota 
(Ramasundara et al. 2009, Salzman et al. 2007). 
 
1.2.3.1.2. Classes of Defensins 
Defensins are classified as α- or ß-defensins based on the position of 3 
intramolecular disulfide bridges (Nissen-Meyer and Nes 1997). 6 α-defensins (HNP1-
4, HD5 and HD6) and 6 ß-defensins (HBD1 to 6) have been identified in humans 
(Table 1) (Bensch et al. 1995, Ganz et al. 1985, Garcia et al. 2001a, Garcia et al. 
2001b, Harder et al. 1997, 2001, Ramasundara et al. 2009, Yamaguchi et al. 2002). 
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Table 1. Defensin in the gut (modified from Ramasundara et al. 2009) 
 
Precursor size 
Mature 
peptide size 
Cystein linkages Defensin Tissue distribution Stimuli 
α-defensins ~90-105 aa ~30-34 aa 1-6, 2-4, 3-5 HNP 1-4 Sparse lamina propria 
neutrophils. In active 
inflammation seen in scattered 
intestinal epithelial cells. 
Increased in active 
inflammation but possibly a 
result of increased neutrophil 
influx. 
    HD5-6 Paneth cells and some villous 
epithelial cells in normal 
duodenum, jejunum and ileum 
Constitutively expressed, 
however processing is 
required for biological activity. 
β-defensins ~60-70 aa ~35-44 aa 1-5, 2-4, 3-6 HBD1 Colonic epithelia (and some 
other mucosal epithelia) 
Constitutively expressed 
    HBD2-4 Colonic epithelia (and some 
other mucosal epithelia) 
Colonic plasma cells 
IL-1α and entero-invasive 
bacteria 
HBD, human β-defensin; HD, human α-defensin; HNP, human neutrophil peptides; IL, interleukin. 
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1.2.3.1.2.1. Human α-defensins 
Human α-defensins provide antimicrobial host defence throughout the 
periphery and small intestine through their expression and release from granulocytic 
neutrophil and Paneth cell populations (Ganz et al. 1985). Human α-defensins are 
synthesized as larger, inactive pro-peptide molecules and the mature, active proteins 
result from post-translational processes (Porter et al. 1998, Valore et al. 1996). In the 
small bowel, human α-defensins (HD) 5 and 6 are most commonly expressed at the 
base of the crypts of Lieberkühn. Human defensin 5 and 6 (HD5, HD6) is primarily 
expressed in the epithelial intestinal Paneth cells (Ghosh et al. 2002) as inactive pro-
peptide. They are cleaved into active mature forms by trypsin and trypsinogen stored 
in Paneth cell granules (Dann and Eckmann 2007, Salzman et al. 2003). Human α-
defensins 1-4, known also as human neutrophil peptides (HNP), are present in 
azurophil granules of polymorphonuclear cells-forming part of their armory and hence 
contributing to innate immunity at a systemic level (Cunliffe 2003). Their expression 
in the gut coincides with the presence of lamina propria neutrophils (Cunliffe 2003). 
 
1.2.3.1.2.2. Human ß-defensins 
Human ß-defensins are produced by epithelial cells that are part of both the 
innate and adaptive immune responses (Harder et al. 1997, 2001, Singh et al. 1998, 
Yang et al. 1999). In contrast to human α-defensins, human ß-defensins are not 
expressed as pro-forms. Epithelial cells constitutively express HBD1. HBD2, 3 and 4 
are induced in the skin as well as in urinary, gastrointestinal and respiratory epithelia 
by stimulation of epithelial cells by contact with microorganisms or cytokines such as 
TNF-α and IL-1β (Harder et al. 1997, Raj and Dentino 2002).     
Since innate immune responses in the gut are directed against luminal 
bacteria, a defect in the expression and/or function of defensins could give rise to an 
increase in frequency and severity of intestinal infection (Fellermann et al. 2003). 
Many fields of investigation agree that such a deficiency could lead to gradual 
bacterial invasion, inflammation and a loss of tolerance to gut bacteria 
(Ramasundara et al. 2009).  
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1.3.    Inflammatory Bowel Diseases (IBD) 
Inflammatory Bowel Diseases (IBD) are chronic, relapsing and debilitating 
conditions that have significant impact on quality of life. Inflammatory bowel disease 
includes two main conditions, ulcerative colitis (UC) and Crohn´s disease (CD) which 
are defined based on characteristic endoscopic and histological finding. UC is 
characterized by superficial inflammation limited to the mucosa of the colon. In 
contrast, CD is characterized by discontinuous skip lesions that can occur anywhere 
in the gastrointestinal (GI) tract with transmural inflammation and non-caseating 
granulomas.  
The pathogenesis of IBD is not clearly understood and its presentation 
regarding disease localization, progression and response to therapies is still under 
investigation. The high concordance rates of CD among monozygotic twins suggest 
the role of genetics in IBD pathogenesis in Jess's study (Jess et al. 2005). The 
evidence of this is seen in the identification on NOD2/CARD 15 allele variants and 
more recently, single nucleotide polymorphism (SNPs) in the autophagy related 16-
like 1 (ATG16L1) gene which are associated with increased risk of developing CD 
(Hampe et al. 2007). On the other hands, the increased incidence of CD over the last 
50 years, especially in developed nation, has linked environmental influences such 
as increased hygiene during infancy and provision of better house-hold amenities to 
increased susceptibility of an inappropriate response to GI infection later in life (Gent 
et al. 1994). Therefore, IBD is known to involve a combination of genetic 
susceptibility and environmental influences.  
The most commonly accepted aetiology of IBD is a loss of tolerance to 
commensal microbiota. The normal intestine maintains a balance between factors 
that activate the host immunity (gut bacteria, dietary antigens, endogenous 
inflammatory stimuli) and the host defences that maintain the integrity of the mucosa 
and down-regulate the inflammatory response (Marks and Segal 2008). Alterations in 
the composition of the gut microbiota may give way to an increase in virulent species 
and a lack of protective species (Sartor 2008). Hence the host immune system is 
overwhelmed by bacterial antigens in the gut lumen and an ineffective down 
regulation shifts the balance toward immune-mediated intestinal injury. Also 
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alteration of the bowel flora by either antibiotics or the use of specific dietary changes 
can ameliorate the symptoms of IBD and help maintain remission (Farrell and 
LaMont 2002, Marks and Segal 2008). In contrast to normal mucosa containing 
relatively small numbers of bacteria, some studies demonstrate adherent and 
invading bacteria in the mucosa of patient with IBD (Wehkamp et al. 2005). Overall, 
the evidence suggests that alteration of commensal bacteria and the cellular 
response of inflammation are intrinsic to IBD pathogenesis.  
A detailed understanding of the host responses and molecular events 
consequent to changes in the intestinal flora is not yet available. The expression and 
regulation of defensins produced in the intestinal mucosa are altered in IBD. 
Therefore, these host defense proteins may play a role in perpetuating or even 
inciting changes in gut microbiota and hence contribute to IBD (Ramasundara et al. 
2009).  
 
1.3.1. Defensin deficiency in inflammatory bowel diseases 
 1.3.1.1. The alpha defensin deficiency in Crohn´s disease 
In ileal Crohn´s disease, the decreased expression of the α-defensins HD5 
and HD6 was demonstrated by Wehkamp and his colleagues and it results in a 
defective antimicrobial shield in humans (Wehkamp et al. 2004b, Wehkamp et al. 
2005). Mutations in the NOD2 (nucleotide-binding oligomerization domain 2) gene, 
an intracellular receptor for bacterial muramyl dipeptide, are clearly associated with 
ileal Crohn´s disease (Hugot et al. 2001, Ogura et al. 2001). It is noteworthy that 
Paneth cells, which are responsible for an effective antibacterial shield in the small 
intestine, also express NOD2 (Lala et al. 2003). Wehkamp and his colleagues also 
found a pronounced decrease of alpha-defensin transcripts in patients of Crohn´s 
disease with a NOD2 mutation as compared to the wild type (Wehkamp et al. 2004b, 
Wehkamp et al. 2005). These studies implicate that the specific deficiency of Paneth 
cell defenses in ileal Crohn´s disease, which is even more pronounced in case of 
NOD2 mutations, results in a dysfunction of the mucosal barrier. The defect in innate 
immune defense of the ileal mucosa appears to be primary and could cause and/or 
maintain this inflammatory disease. 
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Wnt signaling is one of the crucial pathways in the differentiation from the 
intestinal stem cell towards the Paneth cell. In particular the Wnt transcription factor 
TCF4 is a known regulator of Paneth cell differentiation and also alpha-defensin 
expression (van Es et al. 2005). The Wehkamp´s research group was able to show a 
reduced expression of TCF4 in patients with ileal Crohn´s disease as compared to 
colonic Crohn´s disease and ulcerative colitis (Wehkamp et al. 2007b). Remarkably, 
this decrease of TCF4 in ileal Crohn´s disease was independent of the degree of 
inflammation and independent of the NOD2 genotype and TCF4 expression 
correlated with HD5 and HD6 (Wehkamp et al. 2007b). Overall, a defect in intestinal 
stem cell differentiation towards Paneth cells mediated via the Wnt signaling 
transcription factor TCF4 could result in a defective antibacterial shield in ileal 
Crohn´s diseases by the absence of a sufficient expression of the protective Paneth 
cell defensins HD5 and HD6.  
 
1.3.1.2. The beta-defensin deficiency in Crohn´s disease 
The beta-defensins HBD1-3 are preferentially expressed in the colon. HBD1 is 
constitutively expressed in Crohn´s disease independent of the grade of inflammation, 
whereas HBD2 and HBD3 are inducible in intestinal bowel disease (Fahlgren et al. 
2003, O'Neil et al. 1999, Wehkamp et al. 2003, Wehkamp et al. 2002). This 
deficiency of HBD2 expression in Crohn´s colitis was also confirmed on the protein 
level by immunohistochemistry (Wehkamp et al. 2002). HBD2 and HBD3 are strongly 
correlated to each other, especially in case of inflammation (Fahlgren et al. 2003, 
Wehkamp et al. 2003). The observed colonic defect of the antimicrobial barrier 
caused by a diminished expression of beta-defensins was supported by a recent 
study which showed a significantly lower bacterial killing using biopsy extracts from 
Crohn´s disease patients compared to ulcerative colitis and healthy controls (Nuding 
et al. 2007).  
In humans, the beta-defensins HBD2 and HBD3 are neighboring genes on 
chromosome 8p23.1. The DNA copy number of this beta-defensin gene cluster is 
highly polymorphic within the healthy population (Hollox et al. 2003). A genome wide 
copy number profiling using a DNA microarray showed that the defective induction of 
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HBD2 and HBD3 in colonic CD may be due to a lower gene copy number in this 
gene area (Fellermann et al. 2006). The number of HBD2 gene copies was shifted to 
lower numbers in colonic CD as compared to controls (3 vs 4) (Fellermann et al. 
2006). Since patients with 3 or less HBD2 gene copies were shown to have a 
significantly higher risk of developing colonic CD as compared to individuals with four 
or more copies, the number of HBD2 gene copies seems to be functionally relevant 
(Fellermann et al. 2006). 
Therefore, a lower HBD2 gene copy number in the beta-defensin locus 
predisposes to colonic CD, which is most likely mediated through a diminished beta-
defensin expression. 
 
1.3.1.3. Beta defensins deficiency in ulcerative colitis 
Expression of the inducible β-defensins is significantly increased in areas of 
active inflammation in UC. Human β-defensin 2 expression is significantly greater in 
UC compared to controls and also to colonic CD patients (Wehkamp et al. 2002). 
Similarly, the expression of HBD3 is strongly correlated with HBD2 and is also 
greater in UC than in controls (Wehkamp et al. 2003). In contrast, non-inflamed UC 
samples showed no significant difference in expression of HBD2 compared to control, 
indicating that the increased expression of these β-defensins occurs only in active 
inflammation (Wehkamp et al. 2003). Nuding and colleagues found that colonic 
samples from patients with UC contained significantly more plasma lineage cells than 
colonic samples from patients with CD and control patients as defined by CD138 
staining (Nuding et al. 2007). Ulcerative colitis tissue contained on average 16.4 % 
CD138 positive cells compared to 7.8 % for CD and 8.3 % for controls. The high 
concentration of β-defensin expressing colonic plasma cells in the mucosa seen in 
UC could account for the higher levels of β-defensin detected. In addition, the high 
concentration of pro-inflammatory cytokines such as IL-1α and entero-invasive 
bacteria present in the inflamed tissue of UC, may also contribute. The antimicrobial 
peptides are appropriately upregulated consequent to the inflammatory events and 
not likely have a role in the pathogenesis of the disease in UC.   
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Table 2. Antimicrobial peptide expression in ulcerative colitis, colonic and ileal Crohn´s disease (modified from Wehkamp et al. 2009). 
UC (colon) CD (colon) CD (ileum) 
Normal expression of β-defensin HBD1 
and regular induction of HBD2, HBD3 and 
HBD4 
Regular induction of cathelicidin LL37 
HD5 and HD6 expression due to 
metaplastic Paneth cells 
Regular induction of BPI  
Attenuated induction of β-defensins HBD2, 
HBD3 and HBD4 
Attenuated induction of cathelicidin LL37 
HD5 and HD6 expression due to 
metaplastic Paneth cells 
Regular induction of BPI 
Overall reduced mucosal antibacterial 
activity towards different bacteria 
Specific reduction of ileal Paneth cell 
defensins (HD5 and HD6), even more 
pronounced in patients with a NOD2 
mutation (in both cases independent of the 
grade of histological inflammation and not 
observed in inflammatory controls) 
Regular induction of BPI 
Overall reduced mucosal antibacterial 
activity towards different bacteria 
 
UC: Ulcerative Colitis 
CD: Crohn´s disease 
BPI: Bactericidal/Permeability Increasing protein 
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1.4. Aims of this thesis 
As mentioned above, the gut of CD patients possesses a low amount of 
antimicrobial peptides, especially defensins because of a primary defect of defensin 
synthesis. Therefore, we constructed defensin-producing and -secreting probiotic 
EcN bacteria for supplementing the lacking endogenous defensin synthesis.  
 Expression of defensins in probiotic EcN 
Small cationic antimicrobial peptides have already been successfully 
synthesized in E. coli by recombinant DNA methods (Piers et al. 1993). However, 
there are several pitfalls using E. coli as the host cell for cationic antimicrobial 
peptide expression, such as the host-killing activity of the product and its 
susceptibility to proteolytic degradation. The fusion expression of the target peptide 
with a partner alleviates these problems. However, there arises another problem in 
that most fusion products are inactive or produced in an insoluble form (Lee et al. 
2000; Piers et al. 1993). It has been reported that a fusion expression system with 
thioredoxin (TrxA) resulted in an increased yield of soluble products (LaVallie et al. 
2000). This has been observed for HBD2 and HBD3 (Huang et al., 2006; Xu et al., 
2006).  
However, it has not been attempted to produce antimicrobial peptides i.e. 
defensins in probiotic bacteria. EcN was selected because this probiotic strain was 
already licensed as a medication for therapeutic purposes. Therefore, the primary 
aim of this thesis was to achieve the expression of defensins, HD5 and HBD2 in EcN. 
HD5 is encoded as an inactive proform and the inactive proform of HD5 should not 
affect viability of EcN. HBD2 was selected because this defensin is induced in Caco-
2 cells by EcN via its flagellin and its induction in Crohn’s colitis is typically impaired 
(Schlee et al. 2007, Gersemann et al. 2008).   
 Secretion of defensins by recombinant E. coli strains  
The second aim of this thesis was the efficient secretion of a defensin protein 
by the producing bacterial cells. E. coli protein YebF (10.8 kDa) is a soluble 
endogenous protein secreted into the medium and it is used as a carrier for 
transgenic proteins (Zhang et al., 2006). It was reported that passenger proteins 
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linked to the carboxyl end of YebF are efficiently secreted by the respective 
recombinant E. coli K-12 strain. Therefore, YebF was applied and used as the fusion 
partner for construction of recombinant EcN secreting a defensin.  
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2. Materials 
 
2.1. Bacterial strains 
All strains used/constructed in this study are listed in table 3. 
 
Table 3. Strains used in this study. 
Strains Characteristics References/ Sources 
BL21 (DE3) F– ompT gal dcm lon hsdSB(rB
- mB
-) λ(DE3 
[lacI lacUV5-T7 gene 1 ind1 sam7 nin5]) 
(Sambrook and 
Russell 2001) 
BL2171 KmR, BL21 harbouring plasmid pCON7-71 (Anthony et al. 2004) 
BL2174 KmR, BL21 harbouring plasmid pCON7-74 (Anthony et al. 2004) 
BL2186 KmR, BL21 harbouring plasmid pCON3-86B (Anthony et al. 2004) 
BL2171HD5 KmR, BL21 harbouring plasmid pCON71HD5 this study 
BL2174HD5 KmR, BL21 harbouring plasmid pCON74HD5 this study 
BL2186HD5 KmR, BL21 harbouring plasmid pCON86HD5 this study 
BL21T73 ApR, BL21 harbouring plasmid pT7-3 this study 
BL21T74 ApR, BL21 harbouring plasmid pT7-4 this study 
BL21T73HD5 ApR, BL21 harbouring plasmid pT73HD5 this study 
BL21T74HD5 ApR, BL21 harbouring plasmid pT74HD5 this study 
DH5α F´Phi80dlacZ DeltaM15 Delta(lacZYA-argF) 
U169 deoR recA1 endA1 hsdR17 (rk
-, mk
+) 
phoA supE44 thi-1 gyrA96 relA1) 
(Bethesda Research 
Laboratories 1986) 
EcNnirB5 TcR, EcN harbouring plasmid pNIR5 this study 
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EcNbla5 TcR, EcN harbouring plasmid pBLA5 this study 
EcNlac5 TcR, EcN harbouring plasmid pLAC5 this study 
EcNacrB5 TcR, EcN harbouring plasmid pACRB5 this study 
EcN1219 ApR, EcN harbouring plasmid pAR1219  this study 
EcNc1219 ApR, EcNc (EcN cured from both cryptic 
plasmids) harbouring plasmid pAR1219  
this study 
EcN100 ApR, KmR, EcN harbouring plasmids 
pAR1219 and pET-28a(+) 
this study 
EcNc100 ApR, KmR, EcNc harbouring plasmids 
pAR1219 and pET-28a(+) 
this study 
EcN101 ApR, KmR, EcN harbouring plasmids 
pAR1219 and pEAS101  
this study 
EcN102 ApR, KmR, EcN harbouring plasmids 
pAR1219 and pEAS102  
this study 
EcN103 ApR, KmR, EcN harbouring plasmids 
pAR1219 and pEAS103  
this study 
EcNc103 ApR, KmR, EcNc harbouring plasmids 
pAR1219 and pEAS103 
this study 
EcN104 ApR, KmR, EcN harbouring plasmids 
pAR1219 and pEAS104 
this study 
EcN105 ApR, KmR, EcN harbouring plasmids 
pAR1219 and pEAS105 
this study 
EcN106 ApR, KmR, EcN harbouring plasmids 
pAR1219 and pEAS106 
this study 
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SK22D105 ApR, KmR, SK22D (EcN´s isogenic microcin-
negative mutant) harbouring plasmids 
pAR1219 and pEAS105  
this study 
SK22D106 ApR, KmR, SK22D harbouring plasmids 
pAR1219 and pEAS106  
this study 
 
2.2. Plasmids  
All plasmids used and generated in this study are listed in table 4. 
Table 4. Plasmids used in this study. 
Plasmids Characteristics Reference/ Sources 
pCON7-71 
KmR, low-copy number expression vector, 
which utilize the lactose promoter/operator 
system 
(Anthony et al. 2004) 
pCON7-74 
KmR, low-copy number expression vector, 
which utilize the lactose promoter/operator 
system 
(Anthony et al. 2004) 
pCON3-86B 
KmR, low-copy number expression vector, 
which utilize the lactose promoter/operator 
system 
(Anthony et al. 2004) 
pCON71HD5 
KmR, pCON7-71 containing nHD5 gene 
under the control of the lactose promoter 
this study 
pCON74HD5 
KmR, pCON7-74 containing nHD5 gene 
under the control of the lactose promoter 
this study 
pCON86HD5 
KmR, pCON3-86B containing nHD5 gene 
under the control of the lactose promoter 
this study 
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pGEM T-
easy vector  
ApR, Convenient system for the cloning of 
PCR products with single 3'-T overhangs 
Promega, USA 
pMW211 
ApR, Plasmid containing DsRed gene under 
the control of acrB promoter 
(Sorensen M. et al. 
2003) 
pMUT1-Tc Tc
R, pMUT1 with tetA cassette Sibylle Oswald 
pNIRB5 
TcR, pMUT1-Tc containing nHD5 gene under 
the control of nirB promoter 
this study 
pBLA5 
TcR, pMUT1-Tc containing nHD5 gene under 
the control of bla promoter 
this study 
pLAC5 
TcR, pMUT1-Tc containing nHD5 gene under 
the control of lac promoter 
this study 
pACRB5 
TcR, pMUT1-Tc containing nHD5 gene under 
the control of acrB promoter 
this study 
pAR1219 
ApR, pBR322 derived plasmid with lac UV5 
promoter encoding the T7 promoter 
(Davanloo et al. 1984) 
pYebF01 
ApR, Plasmid containing yebF-gene under 
the control of acrB promoter 
Stephanie Weibel 
pET-28a(+) 
KmR, Plasmid vector for cloning genes under 
the expression control of the T7 promoter 
and for creating a fusion protein containing 
either an N- or a C-terminal His-tag. 
Novagen, USA 
pEAS101 
KmR, pET-28a(+) containing nHBD2-gene 
under the control of the T7 promoter and 
encoding HisHBD2 fusion protein with an N-
terminal His-tag 
this study 
pEAS102 Km
R, pET-28a(+) containing nMHBD2-gene 
under the control of the T7 promoter and 
this study 
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encoding HisMHBD2 fusion protein with an 
N-terminal His-tag 
pEAS103 
KmR, pET-28a(+) containing nHD5-gene 
under the control of the T7 promoter and 
encoding HisHD5 fusion protein with an N-
terminal His-tag 
this study 
pEAS104 
KmR, pET-28a(+) containing nMHD5-gene 
under the control of the T7 promoter and 
encoding HisMHD5 fusion protein with an N-
terminal His-tag 
this study 
pEAS105 
KmR, pET-28a(+) containing yebF gene 
under the control of the T7 promoter and 
encoding YebF protein  
this study 
pEAS106 
KmR, pET-28a(+) containing yebF and 
nMHBD2 genes and under the control of the 
T7 promoter and encoding YebFMHBD2 
fusion protein 
this study 
pT7-3 
ApR, expression vector into which genes can 
be cloned under the control of the T7-RNA-
polymerase   
(Tabor and Richardson 
1985) 
pT7-4 
ApR, expression vector into which genes can 
be cloned under the control of the T7-RNA-
polymerase 
(Tabor and Richardson 
1985) 
pT73HD5 
ApR, pT7-3 containing nHD5 gene under the 
control of the T7-RNA-polymerase 
this study 
pT74HD5 
ApR, pT7-4 containing nHD5 gene under the 
control of the T7-RNA-polymerase 
this study 
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2.3. Oligonucleotides 
 Oligonucleotides for PCR reaction and sequencing were synthesized by 
Eurofins MWG Operon. All primers designed for and used in this study are listed in 
Table 5. 
Table 5. Primers used for amplification and subsequent cloning into vector pET-28a(+). 
Primer Sequence 
Applications and 
relevant proterties 
pMUTHD5F1 
5’- TAGAAAAGGCCTCAGGAGGC – 3’ 
                       StuI  
5’- Amplification of 
nHD5 gene for cloning 
in pMUT1 
pMUTHD5R1 
5’- CCGGGCTGCAGGAATTCGAT -3’ 
                                    EcoRI 
3’- Amplification of 
nHD5 gene for cloning 
in pMUT1 
nirBF1 
5’- CCCTCGAGACGAATTCGCC-3’ 
                                 EcoRI 
5’- Amplification of nirB 
gene for cloning in 
pMUT1 
blaF1 
5’- CATTTATCAGGCCTATTGTCT-3’ 
                            StuI 
5’- Amplification of bla 
promoter gene for 
cloning in pMUT1 
blaR1 
5’- GTTTATTTTTCTGAATTCATTCAA - 3’ 
                                  EcoRI 
3’- Amplification of bla 
promoter gene for 
cloning in pMUT1 
lacF1 
5’- CGTAATCATAGGCCTAGCTG -3’ 
                               StuI 
5’- Amplification of lac 
promoter gene for 
cloning in pMUT1 
lacR1 
5’- CCGACTGGAATTCGGGCAGT -3’ 
                         EcoRI 
3’- Amplification of lac 
promoter gene for 
cloning in pMUT1 
acrBF1 
5’- GACGTGGGAATTCCCAGGTT -3’ 
                         EcoRI 
5’- Amplification of 
acrB gene for cloning 
in pMUT1 
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acrBR1 
5’- ATGATACAGGCCTTCGCAAA -3’ 
                          StuI 
3’- Amplification of 
acrB gene for cloning 
in pMUT1 
CONHD5F1 
5’-TAGGCGGTAGTCGACAAGAA -3’ 
                               SalI   
5’- Amplification of 
nHD5 gene for cloning 
in plasmids pCON and 
pT7 
CONHD5R1 
5’-GCAGGAATTCGATATCAAGCT -3’ 3’- Amplification of 
nHD5 gene for cloning 
in plasmids pCON and 
pT7 
PURERBSF1 
5’-TAAGAAGGAGATATACCAAT 
                   RBS 
GCGTACCATTGCCATTCT -3’ 
5’- Generation of RBS 
for expression by “In 
Vitro Protein Synthesis 
Kit” (NEB, USA) 
PURER1 
5’-TATTCATCATTAACGGCAGCACAGAC 
C -3’ 
3’- Amplification of 
nHD5 gene for 
expression by “In Vitro 
Protein Synthesis Kit” 
(NEB, USA) 
PURET7F1 
5’-GAAATTAATACGACTCACTA 
                      T7 promoter 
TAGGGAGACCACAACGGTTTC 
CCTCTAGAAATAATTTTGTTTAA 
CTTTAAGAAGGAGATATACCA -3’ 
                    RBS 
5’- Generation of T7 
promoter and RBS for 
expression by “In Vitro 
Protein Synthesis Kit” 
(NEB, USA) 
HBD2F1 
 
 
5’- CTTTAAGAATTCATGCGTGTT -3’ 
                     EcoRI 
 
5’- Amplification of 
nHBD2 gene for 
cloning in pET-28a(+) 
 
HBD2R1 5’- CTTATTAAGCTTTCATTACGGT -3’   3’- Amplification of 
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                    HindIII nHBD2 gene for 
cloning in pET-28a(+) 
MHBD2F1 
 
5’- CTGCCGGGTGAATTCGGTG -3’ 
                              EcoRI 
5’- Amplification of 
nMHBD2 gene for 
cloning in pET-28a(+) 
HD5F1 
 
5’- TCAGGAGGCCGGATCCATG -3’  
                                 BamHI 
5’- Amplification of 
nHD5 gene for cloning 
in pET-28a(+) 
HD5R1 
 
5’- GCAGGAATTCGATATCAAGCTT -3’ 
                                              HindIII 
3’- Amplification of 
nHD5 gene for cloning 
in pET-28a(+) 
MHD5F1 
 
5’- GTACCAGCGGATCCCAGG -3’ 
                           BamHI 
5’- Amplification of 
nMHD5 gene for 
cloning in pET-28a(+) 
YebFF1 
 
5’- TAGAGAGCTCCCATGGAGAA -3’ 
                                 NcoI 
5’- Amplification of 
yebF gene for cloning 
in pET-28a(+) 
YebFR1 
 
5’- TCTCGAGGATATCTCATT -3’ 
          XhoI   
3’- Amplification of 
yebF gene for cloning 
in pET-28a(+) 
T7F1 
5’-TAATACGACTCACTATAGGG -3’ 5’- sequencing primer 
for the insert in pET-
28a(+)  
T7R1 
5’- GCTAGTTATTGCTCAGCGG -3’ 3’- sequencing primer 
for the insert in pET-
28a(+) 
 
2.4. Chemicals, enzymes and antibodies 
All chemicals used in this study were purchased from the following companies: 
Roche Diagnostics (Switzerland), Promega (USA), QIAGEN (Germany), Merck 
(USA), Roth (Germany), Sigma-Aldrich (USA), Difco (USA), Calbiochem (Germany), 
Peptanova (Germany), Spectrum Laboratories, Inc. (USA). 
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Antibodies and antiserums were provided by Dianova (Germany), Cell signalling 
(USA) and Macherey-Nagel, (Germany). 
 
All restriction enzymes and T4 DNA ligase were purchased from NEB (USA).   
 
Kits were used as follows: 
• “QIAGEN Plasmid Mini Kit”, QIAGEN (Germany) 
• “QIAquick Gel Extraction Kit (PCR purification Kit)”, QIAGEN (Germany) 
• “ABI Prism BigDye Terminator Cycle Sequencing Ready Reaction kit”, Applied 
Biosystems (USA) 
• “PURExpress In Vitro Protein Synthesis Kit”, NEB (USA) 
• “Protein Refolding Kit”, Novagen (USA) 
Antibodies and Antiserums 
 Anti-HBD2 rabbit polyclonal antiserum (was provided by Tomas Ganz at  
          UCLA) 
 Anti-HD5 rabbit polyclonal antiserum (was offered by Edith Porter at CSLA) 
 Anti-HD5 mouse monoclonal antibody (Hycult biotechnology, Germany) 
 Anti-ß-galactosidase mouse monoclonal antibody (Cell signaling, USA) 
 Anti-Maltose binding protein rabbit polyclonal antiserum (NEB, USA)  
 HRP-conjugated polyclonal goat anti-rabbit serum (Dianova, Germany) 
 HRP-conjugated polyclonal rabbit anti-mouse serum (Dako, Denmark)   
 
2.5. Technical equipments 
Autoclave Fedegari FOM/B50 
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Biomedis Tecnoclav  
H+P Varioclav 
Balance IL-180, Chyo Balance Corp. 
Clean bench Nuaire Class II Type A/B3 
Centrifuges (cooling) 
 
                     (table top) 
Heraeus Megafuge 1.0R 
Heraeus Biofuge 13R 
Eppendorf Centrifuge 5415C 
Electrophoresis chamber 
               for agarose gel 
                 for protein gel 
 
Harnischmacher Midi-large 460.000 
Bio-Rad MiniProtean 3 Cell 
Electroporator Gene Pulser Bio-Rad GenePulser XCell 
Incubators Heraeus B5050E 
Ice machine Scotsman AF30 
Luminescence image analyzer Image Quant LAS4000 
Magnetic stirrer Model L-81 
Microwave Moulinex Micro-Chef FM 2910 
pH-Meter WTW Multiline P4 
Photometer  Amersham Ultrospec 3100 pro 
Pipettes (20 µl, 200 µl, 1000 µl) Abimed Discovery Starter-Kit 
Pipette helper  Brand accu-jet pro 
Power supply  Consort E455 
Refrigerator                   
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                                       -20 °C 
                                       -80 °C 
Privileg  
Thermo Scientific 
Sequencer ABI PRISM 310 Genetic Analyzer 
Shaking incubator Certomat U, Certomat H 
New Brunswick Scientific Innova 4300 
Shaking table GLW L-40 
Sonicator Branso Sonifier B12 
Thermocycler  Biometra T3 
UV-transilluminator NTAS 
Vortexer Bender & Hobein AG Vortex Genie 2 
Water bath Memmert Wasserbad 
 
2.6. Media 
All media were autoclaved at 121 °C for 20 min. And 1.5 % (w/v) agar (difco) 
was added for agar plates. 
LB- (Luria-Bertani-) Medium (Sambrook and Russell 2001) 
             Tryptone                                              10 g 
             Yeast extract                                         5 g 
             NaCl                                                      5 g 
             dH2O                                              ad 1000 ml, pH 7.5 
 
Turbo Medium 
             Tryptone                                              20 g   
             Yeast extract                                       10 g 
32 
 
             NaCl                                                      5 g 
             Glycerol                                                 2 g 
             KH2PO4                                               6.8 g 
             K2HPO4                                             11.4 g  
             dH2O                                             ad 1000 ml     
 
Tryptic Soy Broth (TSB) 
            TSB                                                      30 g   
            dH2O                                              ad 1000 ml     
 
SOC medium 
           Tryptone                                                    2 g 
           Yeast extract                                          0.5 g 
           NaCl                                                       0.5 g 
           KCl                                                     0.186 g 
           MgCl                                                  0.952 g 
           MgSO4                                               2.408 g 
           glucose                                              3.603 g           
           dH2O                                              ad 1,000 ml        
 
2.7. Antibiotics 
Antibiotics were sterile filtrated and stored at -20 °C.  
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Antibiotics 
final 
concnetration 
Solvent 
Ampicillin (with Kanamycin 10 
µg/ml)  
20 µg/ml dH2O, sterile filtrated 
Ampicillin 50 µg/ml dH2O, sterile filtrated 
Kanamycin (with Ampicillin 20 
µg/ml) 
10 µg/ml dH2O, sterile filtrated 
Kanamycin 30 µg/ml dH2O, sterile filtrated 
Tetracyclin 10 µg/ml 
100 % EtOH, sterile 
filtrated 
 
2.8. Enzymes and solutions 
 The buffer supplied by the manufacturer and solutions were used for enzyme 
reactions. The details of buffer solutions were described under the respective 
methods sections. 
 
2.9. DNA and protein markers 
2.9.1. DNA marker 
 To determine the size of DNA fragments in agarose gels, the Generuler 1 kb 
DNA ladder and 100 bp DNA ladder were purchased from MBI Fermentas and were 
used.  
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2.9.2. Protein marker 
 'Prestained protein ladder' from MBI Fermentas was used for determination of 
the molecular weight of proteins separated by polyacrylamide gel 
electrophoresis.
 
 
 
Used Protein marker 
Prestained protein ladder 
Source: http://www.fermentas.com 
  
 Used DNA standard marker 
(A) GeneRuler 1 kb DNA Ladder 
 (B) GeneRuler 100 bp DNA Ladder 
A B 
Source: http://www.fermentas.com 
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3. Methods 
 
3.1. Nucleic acid methods 
3.1.1. Design of HBD2 and HD5 genes with optimized codon usage for 
expression in Escherichia coli  
The sequences of human beta-defensin 2 gene (GenBank accession No 
AF040153) and human alpha-defensin 5 gene (GenBank accession No M97925) 
were optimized for high expression in E. coli according to the codon usage table 
(http://www.kazusa.or.jp/codon/). Optimized nHBD2 and nHD5 genes were produced 
by Eurofins MWG Operon (Ebersberg, Germany) (nHBD2) and Sloning 
Biotechnology (Munich, Germany) (nHD5), respectively. All primers designed for and 
used in this study are listed in table 5. 
 
3.1.2. Plasmid DNA extractions  
3.1.2.1. Rapid method for the isolation of plasmid DNA  
3 ml of overnight culture was centrifuged at 12,000 g for 5 min and the pellet of 
bacterial cells was resuspended in 200 μl of Buffer I and then 200 μl of Buffer II was 
added and mixed thoroughly by inverting several times. It was incubated at room 
temperature (RT) for 5 min. After adding 200 μl of ice-cold Buffer III, it was briefly 
mixed again and incubated on ice for 5 min. Chromosomal DNA and cellular debris 
are then removed by centrifugation at 12,000 g for 10 min. The clear supernatant 
was transferred to a new tube. 420 μl of 100 % ethanol was added and incubated on 
ice for 2 min. After centrifugation at 12,000 g for 10 min, the supernatant was 
discarded. The pellet was washed with 400 μl 70 % ethanol twice and dried. Finally, 
the pellet was dissolved in 40 μl of 10 mM Tris-HCl, pH 7.4 and stored at -20 °C. 
Buffer compositions : 
Buffer I 1 M Tris-HCl, pH 7.5 
0.5 M EDTA, pH 8.0 
RNase (10 mg/ml) 
dH2O 
5 ml 
2 ml 
1 ml 
ad 100 ml 
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Buffer II NaOH  
SDS  
0.2 N 
1 % (w/v) 
 
Buffer III Sodium acetate, pH 4.8  3 M 
 
 
3.1.2.2. Plasmid isolation with Plasmid Mini Kit, QIAGEN 
Plasmid Mini Kit (QIAGEN) was used for the isolation of plasmid DNA. 3 ml of 
overnight culture was collected by centrifugation at 12,000 g for 5 min and the pellet 
was resuspended with 250 μl Buffer P1 and then 250 μl Buffer P2 was added and 
mixed by inverting. And then, Buffer N3 was added and mixed immediately and 
thoroughly using inverting. The mixture was then centrifuged at 12,000 g for 10 min 
and the supernatant was applied to the QIAprep spin column (supplied by the 
manufacturer) by pipetting. After centrifugation for 1 min, the flow-through was 
discarded. The column was washed by adding 500 μl Buffer PB (supplied by the 
manufacturer) and centrifuged for 1 min. After that, it was washed with 750 μl Buffer 
PE (supplied by the manufacturer). The QIAprep column was placed in a clean and 
sterile 1.5 ml tube and DNA was eluted by 10 mM Tris-HCl, pH 8.5.    
Buffer compositions (supplied by the manufacturer) 
P1 Tris/HCl (pH 8.0) 
EDTA 
RNAse A 
50 mM 
10 mM 
100 µg/ml 
 
P2 
 
NaOH 
SDS 
 
200 mM 
1 % (w/v) 
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P3 Potassium acetate (pH 5.5) 3 M 
 
3.1.3. Enzymatic digest of DNA with restriction endonucleases 
 Approximately, 10 µg plasmid DNA dissolved in dH2O was mixed with 5 µl of 
the appropriate 10x NEB buffer and 10 U of restriction enzyme (NEB), so that the 
final volume of the sample was 50 µl. The plasmid DNA was digested at 37 °C for 2 h. 
Afterwards, the restriction enzyme was removed by PCR purification kit (QIAGEN). 
 
3.1.4. Horizontal gel electrophoresis 
 For routine analytical and preparative separation of DNA fragments, horizontal 
gel electrophoresis under non-denaturing conditions was performed using agarose 
gels with 1.5 % (w/v) agarose in running buffer (TAE). 
 To prevent diffusion of the DNA and to have a visible running front, 0.2 volume 
of loading dye was added to the samples before loading. The electrophoresis was 
carried out at 150 V and then stained in an ethidium bromide solution (10 mg/ml), 
washed with water and photographed under a UV-transilluminator.  
                       
   50x TAE buffer:          Tris                                      2 M 
                                      acetic acid (99.7 %)            6 % (v/v) 
                                      EDTA (pH 8.0)                    50 mM 
                                      dH2O                            ad   1,000 ml 
   
 6x loading dye:           bromphenol blue                       0.25 % (w/v) 
                                    Xylene cyanol FF                      0.25 % (w/v) 
                                    Ficoll (Type 400, Pharmacia)    15 % (w/v) 
                                    glycerol                                      30 % (v/v) 
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                                    dH2O                                   ad   50 ml 
                                              
3.1.5. Isolation of DNA fragments from agarose gels 
Agarose pieces containing the DNA fragment of interest were cut out of the gel 
and DNA was purified from agarose gels using the QIAquick Gel Extraction Kit 
(QIAGEN). The piece of agarose containing DNA was subsequently melted at 50 °C 
for 10 min in QG buffer (supplied by the manufacturer). Applying the mixture to a 
QIAquick spin column was followed and then the column was centrifuged for 1 min. 
DNA was bound to the column and the rest of the solution was removed by 
centrifugation. The column was then washed with 750 μl PE buffer (supplied by the 
manufacturer, supplemented with ethanol) and residual PE buffer was removed with 
centrifugation for 1 min. Finally, the DNA was eluted from the column with 20 µl dH2O. 
 
3.1.6. Polymerase chain reaction (PCR) 
 Nucleotide sequences were amplified by PCR since the DNA sequence of the 
PCR product can be selectively altered. 
 The PCR reaction was prepared as following: 
                                  5x Phusion HF polymerase buffer                  20 μl 
                                  10 mM dNTP-Mix                                             2 μl 
                                  0.5 μg/μl Primer 1                                            2 μl 
                                  0.5 μg/μl Primer 2                                            2 μl 
                                  100 ng/μl Template-DNA                                 1 μl 
                                  Phusion HF polymerase                                  1 μl 
                                  dH2O                                                        ad 100 μl 
 
The reaction samples were boiled at 98 °C for 30 s. The amplification of DNA 
was performed under the optimal conditions for 25 cycles. Denaturation condition 
was at 98 °C for 8 s and annealing temperature was determined at Tm+3 °C of the 
lower Tm primer for 20 s and extension was done at 72 °C for 15 s/1 kb. Final 
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extension was performed at 72 °C for 5 min to ensure completely synthesis of all 
DNA fragments. 
 
3.1.7. Dephosphorylation of DNA fragments 
 In order to prevent religation of vector DNA after enzymatic digestion, the 5’ 
end of DNA fragment should be dephosphorylated. Removal of the 5´-phosphate 
group was achieved by adding phosphatase from calf intestine (1 unit) and 10x 
alkaline phosphatase buffer. The samples were incubated at 37 °C for 1 h. 
Afterwards, purification by PCR purification kit (QIAGEN) was done for inactivation of 
phosphatase. 
 
3.1.8. Ligation of DNA fragments  
 Linearized vector and insert DNA after restriction digestion can be ligated 
either due to the presence of sticky ends or by blunt ends ligation. The enzyme for 
the ligation process was the T4-DNA ligase (NEB). Best efficiencies were obtained 
using an insert/vector ratio of 3/1. Reactions were performed at 18 °C for 1 h in a 
final volume of 20 µl containing 2 µl 10x ligation buffer and 1 µl (1 unit) T4 ligase.  
 
3.1.9. Transformation of bacterial cells 
3.1.9.1. Preparation of electrocompetent cells 
 For construction of recombinant strains, the bacterial cell wall and cell 
membrane were made permeable (transformation-competent).  
 For electrocompetent E. coli, 100 ml LB medium were incubated containing 
1.5 ml of overnight culture at 37 °C and grown to OD600 of 0.5. Then the bacterial 
cells were centrifuged at 2,000 g, 4 °C for 10 min. The pellet was washed 2 times 
with sterile ice-cold dH2O. Finally, the washed pellet was resuspended in 150 µl 10 % 
glycerol (v/v) and aliquots (each 80 µl) were transferred to new 1.5 ml tubes and 
stored at -80 °C. 
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3.1.9.2. Transformation of bacterial cells by electroporation 
The translocation of recombinant DNA into the corresponding competent cells 
can be achieved by briefly applying an electrical impulse.   
For electroporation, one vial of 80 µl electrocompetent cells was thawed on ice 
and mixed with 1-2 µl plasmid DNA solution (1-100 ng DNA) and incubated for 15 
min on ice. Then the electrocompetent cells were transferred to a cuvette and 
electroporation was performed in a GenePulser Xcel (Biorad) electroporator with 
settings of 2.5 kV, 200 Ω and 25 μF in the 1-mm-wide GenePulser electroporation 
cuvette. After electroporation, 1 ml of SOC medium was added and incubated at 
37 °C for 1 h in a shaker. Afterwards, bacteria were plated on a selective agar plate. 
The plate was incubated at 37 °C for 18 h. 
 
3.1.10. Sequencing with fluorescent labeled nucleotides (AmpliTaq® FS 
BigDye-Terminator, Perkin Elmer) 
The DNA sequencing was based on the chain termination method (Sanger et 
al. 1977). In order to determine the nucleotide sequences, PCR was carried out with 
different fluorescent dyes labeled ddNTP and these labeled nucleotides can be 
detected on the ABI PRISM 310 Genetic Analyzer using the laser (Perkin Elmer). 
The sample composition for PCR was: 
                        plasmid DNA                                  0.5 μg 
                       10 pM primer                                   1.5 μl 
                        5x buffer (kit component)                  2 μl 
                        premix (kit component)                     2 μl   
                        dH2O                                          ad 10 μl     
 
The subsequent sequencing PCR was performed under the following 
conditions: First, the plasmid DNA was denatured at 94 °C for 3 min. Denaturation at 
94 °C for 30 s, annealing at Tm of the lower Tm primer for 15 s and elongation at 
60 °C for 4min were followed by 25 cycles. Subsequently, the reaction sample was 
precipitated with 90 µl dH2O, 10 µl 3 M sodium acetate (pH 4.6) and 250 µl 100 % 
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ethanol. After centrifugation at 13,000 g for 15 min, the supernatant was removed 
and the pellet was washed with 250 µl 70 % ethanol (v/v). After centrifugation and the 
removal of ethanol, the pellet was dried. The pellet was resuspended in 25 µl Hidi 
formamide (ultrapure and deinoized) and the sample was then analyzed in an ABI 
prism sequencer (Perkin Elmer).  
 
3.2. Protein methods 
3.2.1. Protein expression with “PURExpress In Vitro Protein Synthesis Kit” 
(NEB) 
PURExpress kit is a novel coupled cell-free transcription/translation system 
reconstituted from purified components necessary for E. coli translation. Overlap 
extension PCR can be used to generate template DNA for use with “PURExpress In 
Vitro Protein Synthesis Kit”. In the first round of PCR, PURERBSF1 and PURER1 
were used to add RBS sequences. In the second round of PCR with PURET7F1 and 
PURER1, flanking primers bind the homologous regions of the first round product 
and extension occurred to contain the complete regulatory sequences and tags (Fig. 
2).   
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Fig. 2. Overlap extension PCR to generate linear template DNA, LT_nHD5. 
 
Firstly, solution A and B which were provided by the manufacturer were 
thawed on ice.  
 
The reaction sample composition was: 
    Solution A                    12.5 µl 
    Solution B                         5 µl 
    RNase inhibitor                 1 µl 
    Template DNA                  1 µl (100 ng) 
    dH2O                          ad  25 µl 
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After adding all components, the sample was mixed gently and incubated at 
37 °C for 1 h. The reaction was stopped by placing the tube on ice. Expression of 
protein was analyzed by Western blot. 
 
3.2.2. Protein expression in recombinant strains 
For expression of the target proteins under the control of various promoters 
such as nirB, lac, bla and acrB using pMUT1-Tc, tetracycline (10 µg/ml) and protease 
inhibitor cocktail at a concentration according to the manufacturer (Roche, 
Switzerland) were added in LB medium. EcN harbouring plasmid pNIRB5 was grown 
to an optical density (OD600) of 1.0 and induced without aeration at 37 °C for 24 h for 
expression of HD5 under the control of nirB promoter. Anaerobiosis was achieved by 
sealing tightly using parafilm and incubation without shaking. For induction of HD5 
under the control of lac promoter, 1.0 mM IPTG was added to the grown culture at 
OD600 of 1.0 and culture was incubated at 37 °C for 18 h. EcNacrB5 was induced at 
OD600 of 1 with 4 % ethanol (v/v) and 0.5 M NaCl and incubated at 37 °C for 24 h for 
HD5 expression by the control of acrB promoter. EcN containing pBLA5 was grown 
at 37 °C for 18 h for HD5 production under the control of bla promoter.  
For induction of protein under the control of the T7 promoter, ten microliters of 
glycerol culture of each recombinant strain were added to 10 ml of Turbo medium 
supplemented with ampicillin (20 μg/ml), kanamycin (10 μg/ml) and protease inhibitor 
cocktail according to the instructions of the manufacturer (Roche, Switzerland). 
Cultures were grown at 37 °C for 18 h. Subsequently, 8 ml of each grown culture 
were used to inoculate 800 ml Turbo medium containing ampicillin (20 μg/ml) and 
kanamycin (10 μg/ml) and an appropriate amount of protease inhibitor cocktail. The 
cultures were incubated at 37 °C and expression was induced at an OD600 of 1.0 with 
IPTG (final concentration 1.0 mM). The cells harbouring pAR1219 and an expression 
vector were harvested after incubation at 37 °C or 20 °C at several time points. 
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3.2.3. Cell lysis by sonication 
The induced cells were collected by centrifugation at 6,000 g for 20 min. The 
cells were lysed in LEW buffer by sonication (15 s bursts, 10 times with a 15 s 
cooling period between each burst). Lysed extract was separated from cell debris by 
centrifugation at 10,000 g for 30 min, and then the supernatant was filtrated (0.22 µm, 
Millipore, USA). The filtrate contained the soluble proteins. To yield the insoluble 
proteins, the pellet was further dissolved in 8 M urea. 
 
LEW buffer:                   NaH2PO4                                 50 mM 
                                      NaCl                           300 mM  
                                      pH                                  7.8 
 
3.2.4. Isolation of soluble fusion protein with an N-terminal His-tag by nickel-
affinity chromatography 
The respective protein can be enriched by nickel-affinity chromatography due 
to a His-tag. Protino Ni-TED 2000-packed columns (Macherey-Nagel, Germany) 
were used for the affinity chromatographic purification of the protein. A column was 
equilibrated with 8 ml of LEW buffer and then allowed to drain by gravitation. The 
soluble fraction of cellular proteins was subjected to nickel-affinity chromatography 
and the His-tagged protein was eluted with 9 ml of elution buffer. Desalination was 
performed by dialysis with H2O at 4 °C for 9 h. During this time, water was changed 
two times and then samples were concentrated with Spectra Absorbent (Spectrum 
Laboratories, Inc., USA). Bradford protein assay was used for subsequent protein 
quantification (Bradford 1976) (Roti-Nanoquant, Roth). 
 
Elution buffer:                  NaH2PO4                             50 mM 
                                                            NaCl                                  300 mM 
                                        Imidazole                           250 mM 
                                        pH                                         7.8 
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3.2.5. SDS tricine western blot analysis 
After gel electrophoresis separation of proteins, proteins were transferred to 
an Immobilon PS-Q membrane. Then the proteins were examined by specific 
antibodies. 
 
3.2.5.1. Tricine SDS-PAGE 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) is a 
technique for separating proteins based on their ability to move within an electrical 
field, which is a function of the length of their polypeptide chains and equivalent to 
their molecular weight. This is achieved by adding SDS detergent to remove 
secondary and tertiary protein structures and to maintain the proteins as linear 
polypeptide chains. The SDS coats the proteins, proportional to their molecular 
weight and confers a negative electrical charge to all proteins in the sample which is 
proportional to their molecular weight (Sambrook and Russell 2001). Tricine SDS-
PAGE is commonly used to separate proteins in the mass range of 1-100 kDa 
(Schagger 2006). It is the preferred electrophoretic system for the resolution of 
proteins smaller than 30 kDa.  
For polyacrylamide gel electrophoresis (PAGE), a mini gel chamber was used 
for gels with dimensions of 7 x 9 x 0.1 cm (height x width x depth). Separating and 
stacking gels were prepared with the compositions given below. The prepared gel 
mixture was poured between the previously cleaned glass plates by ethanol and then 
dH2O was overlaid. After polymerization, dH2O was removed and the stacking gel 
was poured onto the separating gel. The wells were formed with a comb in the 
stacking gel.  
Total proteins from whole cells were prepared by centrifugation of induced 
cultures at 13,000 g for 10 min and cells were resuspended in 10 mM Tris-HCl, pH 
7.4. Proteins in the cell-free medium were obtained by centrifugation of 2 ml induced 
culture at 13,000 g for 10 min and sterile filtration (0.22 µm, Millipore, USA). 
Afterwards, the supernatant was precipitated with 10 % trichloroacetic acid (TCA) 
(w/v) at 4 °C for 1 h. After centrifugation at 13,000 g and 4 °C for 15 min, the pellet 
was washed twice by addition of 1 ml 100 % ethanol and once by 1 ml of 70 % 
ethanol (v/v). The final pellet was dissolved in 10 mM Tris-HCl, pH 7.4, SDS-PAGE 
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sample buffer was added at a ¼ volume of each sample and then samples were 
boiled at 95 °C for 5 min. 
Electrophoresis was performed at 50 V for running in the stacking gel and at 
100 V for the separating gel. “Prestained protein ladder” (Fermentas) was used as 
the standard of molecular weight. 
 
Electrode buffers: 
Anode buffer:                    Tris                          0.1 M 
                                          HCl                      225 mM   
                                          pH                              8.9     
 
Cathode buffer:                 Tris                          0.1 M     
                                          Tricine                     0.1 M    
                                          SDS                         0.1 % (w/v)   
                                          pH                            8.25 
 
Sample buffer:                  SDS                                                     12 % (w/v)  
                                         mercaptoethanol                                    6 %  (v/v)  
                                         glycerol                                                 30 % (v/v) 
                                         Coomassie blue G-250                      0.05 % (w/v) 
                                         Tris-HCl, pH 7.0                                  150 mM 
 
12 % separating gel :        3X Gel buffer                                                4.95 ml 
                                         30 % Acrylamide, 0.8 % Bisacrylamide          4.8 ml  
                                         dH2O                                                             3.69 ml   
                                         glycerol                                                           1.5 ml 
                                         10 % (w/v) APS                                                45 μl     
                                         TEMED                                                              6 μl 
 
4% stacking gel:               3X Gel buffer                                                  1.2 ml 
                                         30 % Acrylamide, 0.8 % Bisacrylamide        0.67 ml  
                                         dH2O                                                             3.09 ml   
                                         10 % (w/v) APS                                                40 μl     
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                                         TEMED                                                              4 μl 
 
3x Gel buffer:                   Tris                                                                18.15 g 
                                        SDS                                                               150 mg 
                                        37 % (v/v) HCl                                                4.31 ml         
                                        dH2O                                                          ad   50 ml     
 
3.2.5.2. Western blotting 
After electrophoresis, proteins were transferred to an Immobilon PS-Q 
membrane (Millipore, USA) in Western blot buffers. The specific antibody can make 
visible a particular protein in the membrane. To transfer the protein, the membrane 
and 12 Whatman papers were cut into pieces of the gel size. The membrane was 
soaked with methanol for 30 s and incubated in anode buffer II for 5 min. 6 wet 
papers in anode buffer I were placed on the plate of the blot apparatus and 3 wet 
papers with anode buffer II followed. The membrane was placed on the papers and 
the gel on the membrane. 3 layers of paper soaked with cathode buffer covered the 
gel. Air bubbles were removed before the upper plate of the blot apparatus was 
placed on top. The transfer was performed at 0.8 mM/cm2 for 1 h.  
 
Western blot buffers: 
Anode buffer I:                      Tris                                        0.3 M   
                                              methanol                               20 % (v/v)  
                                              Tween 20                             0.1 % (v/v) 
 
Anode buffer II:                     Tris                                       25 mM 
                                              methanol                              20 % (v/v) 
 
Cathode buffer:                     Tris                                       25 mM   
                                              methanol                              20 % (v/v)   
                                              ε-Amino-n-capronic acid      40 mM 
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3.2.5.3.  Antibody treatment 
After transfer of the protein, the membrane was fixed with 0.01 % 
glutaraldehyde (in TBS) for 20 min and blocked in 5 % (w/v) nonfat milk for 18 h. 
Subsequently, the blot was incubated with primary antibody solution at RT for 1 h. 
The ratio of dilution of primary antibody was dependent on the serum and performed 
in TBS-T with 5 % (w/v) nonfat milk. In order to remove unspecifically bound antibody, 
the blot was washed 3 times with TBS for 10 min. The blot was incubated with 
peroxidase coupled secondary antibodies at RT for 1 h (dilution in TBS-T with 5 % 
(w/v) nonfat milk). Then, three washing steps with TBS-T for 10 min followed and the 
blot was moistened with the chemiluminescent detection solution for 1 min with 
gentle shaking. Afterwards, the blots were processed by the luminescence image 
analyzer (Imagequant LAS 4000).  
 
10x TBS:                 Tris-HCl (pH 7.4)                             500 mM          
                              NaCl                                              1500 mM 
 
TBS-T was prepared with adding of 0.05 % Tween 20 (v/v) to 1x TBS. 
                    
Dilution ratios of antibodies:  
       Anti-HBD2 rabbit polyclonal antiserum                                           1:2,000  
       Anti-HD5 rabbit polyclonal antiserum                                             1:1,000  
       Anti-ß-galactosidase mouse monoclonal antibody                         1:1,000 
       Anti-Maltose binding protein rabbit polyclonal antiserum               1:5,000 
         HRP-conjugated polyclonal goat anti-rabbit serum                        1:10,000     
       HRP-conjugated polyclonal rabbit anti-mouse serum                    1:5,000     
 
 Chemiluminescent detection solution:         Tris, pH 8.5                      0.1 M    
                                                                     coumaric acid                   0.2 mM      
                                                                     Luminol                            1.25 mM   
                                                                     H2O2                                                 0.06 % (v/v)     
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3.2.6. Antimicrobial activity tests 
3.2.6.1. Radial diffusion assay 
Radial diffusion assay was developed by Robert I. Lehrer to measure 
antimicrobial susceptibility (Lehrer et al. 1991). For radial diffusion assays, bacteria 
were grown at 37 °C for 18 h in 5 ml of TSB broth. To obtain mid-logarithmic phase 
bacteria, 5 µl (E. coli K-12 MG1655 and Salmonella enterica serovar Typhimurium 
SL1344) or 50 µl (Listeria monocytogenes) of the overnight cultures were used to 
inoculate 5 ml fresh TSB and incubated for an additional 2.5 h at 37 °C. The bacteria 
were centrifuged at 900 g, 4 °C for 10 min, washed once with cold 10 mM sodium 
phosphate buffer, pH 7.4 and resuspended in 2.5 ml of cold 10 mM sodium 
phosphate buffer. An aliquot containing 4x106 bacterial cells was added to 10 ml of 
previously autoclaved and warm (42 °C) underlay agar. The agar was poured into a 
petri dish and allowed to solidify. Thereafter, a sterile glass pipette (5 mm diameter) 
was used to create wells in the agar. After adding samples to each well, the plates 
were incubated at 37 °C for 4 h and then were overlaid with 10 ml of sterile overlay 
agar maintained in liquid state by keeping at 42 °C. After incubation at 37 °C for 18 h, 
the inhibition zones surrounding the wells were detected.  
 
 
100 mM Sodium phosphate buffer:  200 mM NaH2PO4 ∙ H2O                   4.75 ml 
                                                         200 mM Na2HPO4 ∙ 2 H2O              20.25 ml  
                                                         dH2O                                        ad      500 ml 
                                                         pH                                                       7.4 
 
10 mM Sodium phosphate buffer:  
                                Dilution of 100 mM Sodium phosphate buffer 1:10 with dH2O 
 
Underlay gel:                         EEO agarose                                                0.5 g  
                                              100 mM Sodium phosphate butter                 5 ml    
                                              TSB medium                                                0.5 ml 
50 
 
                                              dH2O                                                    ad     50 ml 
                                              pH                                                                 7.4 
  
Overlay gel:                           EEO agarose                                                0.5 g 
                                              TSB                                                                  3 g 
                                              dH2O                                                     ad     50 ml 
    
3.2.6.2. The killing assay in liquid culture                
Bioactivity of secreted mature fusion HBD2 was tested in liquid culture. E. coli 
K-12 MG1655 and Listeria monocytogenes EGD were used as indicator strains. 2.5 
µg or 5 µg of total proteins from the cell-free supernatant were added to log phase    
E. coli K-12 MG1655 (107 cfu/ml) or Listeria monocytogenes EGD (107 cfu/ml). Each 
test mixture had a volume of 300 µl and contained secreted proteins and bacteria in 
10 mM sodium phosphate buffer, pH 7.4, and 1 % TSB medium. After mixing all 
components in the samples, a 100 µl aliquot of each sample was withdrawn for 
analysis of initial values (time point zero). The residual 200 µl of the samples were 
incubated at 37 °C for 4 h. All samples were serially diluted and aliquots of 100 µl 
were spread on LB agar plates. The plates were incubated at 37 °C for 18 h and then 
the number of colonies was counted. 
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4. Results 
 
4.1. Codon optimization of human beta-defensin 2 and human alpha-defensin 
5 gene for expression in Escherichia coli 
Differences in codon usage between species can affect the quantity and 
quality of the protein expressed by recombinant techniques. Therefore, codons in the 
cDNA of human beta-defensin 2 (HBD2) and human alpha-defensin 5 (HD5) were 
analyzed for rare codons. 
HBD2 (GenBank accession No AF040153) consists of 64 amino acids, 27 
amino acids (42.2 %) of which are encoded by rarely used codons in E. coli. 
Moreover, 6 codons (coding for R2, I13, I25, I37, R45 and R46) play important roles 
in adverse effects on heterogeneous protein expression in E. coli (Kane 1995). 
Particularly, R2, R45 and R46 are encoded by the least used codons (AGG and 
AGA) among the minor codons in E. coli (Fig. 3). The presence of single AGG or 
AGA, and tandem repeats of them were discovered to dramatically reduce the 
maximum level of protein synthesis and may also cause frameshifts with high 
frequency (Spanjaard et al. 1990). 
HD5 (GenBank accession No M97925) consists of 94 amino acids with 29 
amino acids (30.9 %) encoded by low usage codons in E. coli. Among these 29 
amino acids, 6 amino acids are encoded by codons (coding for R2, R25, R55, R62, 
R68 and R90) which may cause adverse effects on protein expression in E. coli (Fig. 
3). 
In order to avoid the potential problems of these rare codons on HBD2 and 
HD5 expression in E. coli, corresponding new genes, nHBD2 (EMBL HE583189) and 
nHD5 (EMBL HE583188) (Fig. 3), were designed where the rare codons were 
replaced by frequently used ones in E. coli according to the codon usage table of     
E. coli (http://www.kazusa.or.jp/codon/). To increase the translation termination signal 
in E. coli, the original stop codon TGA was replaced by two stop codons in series, 
TAATGA, which is the most efficient translational termination sequence in E. coli 
(Hannig and Makrides 1998). 
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nHBD2 and nHD5 were synthesized by Eurofins MWG Operon (nHBD2) and 
Sloning Biotechnology (nHD5), respectively, according to the sequences designed in 
this study. 
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Fig. 3. Comparison of (A) HBD2 and (B) HD5 sequences between original cDNA and modified ones, 
Lane 1: original sequences of the cDNA, (A) HBD2-gene (GenBank accession No AF040153) and (B) 
HD5-gene (GenBank accession No M97925) sequences; Lane 2: optimized sequences of (A) nHBD2-
gene (EMBL HE583189) and (B) nHD5-gene (EMBL HE583188); Lane 3: sequences of corresponding 
amino acids of (A) HBD2 and (B) HD5. 
 
4.2. Construction of recombinant plasmids for the expression of defensins in 
E. coli 
4.2.1. Cloning of nHD5-gene in pMUT1-Tc under the control of various 
promoters 
Plasmid pMUT1-Tc mediating tetracycline resistance is a derivate of pMUT1, 
one of two very stable cryptic plasmids of EcN. pMUT1-Tc was used as a cloning 
vector for the first attempt to clone and express HD5 protein. For that purpose, nHD5 
gene was cloned under the control of one of several promoters such as nirB, bla, lac 
and acrB, respectively. nirB promoter is active under anaerobic condition and bla 
promoter is a constitutive one. Moreover, lac promoter is inducible by IPTG and acrB 
promoter is expressed under stress conditions.  
 
Table 6. Sequences of applied promoters 
Promoter Sequences 
nirB promoter 
CCGTGACTTA AGAAAATTTA 
TACAAATCAG CAATATACCC 
ATTAAGGAGT ATATAAAGGT 
GAATTTGATT  TACATCAATA 
AGCGGGGTTG CTGAATCGTT 
AAGGTAGGCG GTAATAGAA      
AAGAAATC (DQ841278) 
bla promoter 
TTCAAATATG TATCCGCTCA 
TGAGACAAT (AM403094) 
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lac promoter 
AGCTGTTTCC TGTGTGAAAT 
TGTTATCCGC TCACAATTCC 
ACACAACATA CGAGCCGGAA 
GCATAAAGTG TAAAGCCTGG 
GGTGCCTAAT GAGTGAGCTA 
ACTCACATTA ATTGCGTTGCGC 
(U46017) 
acrB promoter 
TATCCATCCC GAAGGTGTTC 
GGTTAGTTTA AGCCACTAAA 
AAGGGGATGC ATTATGGACG 
AATACTCACC CAAAAGACAT 
GATATAGCAC  AGCTTAAATT 
(5501 bp to 5600 bp of pMW211)  
(The numbers in parentheses for nirB, bla and lac are Genbank Accession No.) 
 
 
 
Fig. 4. Physical map of plasmid pNIRB5. pMUT1-Tc harbouring nHD5 gene under the control of nirB 
promoter. 
 
 
55 
 
 
 
 
Fig. 5. Physical map of plasmid pBLA5. pMUT1-Tc harbouring nHD5 gene under the control of bla 
promoter. 
 
 
 
Fig. 6. Physical map of plasmid pLAC5. pMUT1-Tc harbouring nHD5 gene under the control of lac 
promoter. 
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Fig. 7. Physical map of plasmid pACRB5. pMUT1-Tc harbouring nHD5 gene under the control of acrB 
promoter. 
 
Plasmid DNA of pMUT1-Tc, nHD5 and promoters were digested with EcoRI 
and StuI and nHD5 and promoters were ligated into pMUT1-Tc. This approach 
resulted in, four different recombinant plasmids each with one of the promoters from 
the genes nirB, bla, lac and acrB (Figs. 4-7). E. coli K-12 DH5α was transformed with 
the resulting plasmid by electroporation. The colonies obtained were proven to 
contain the favored insert and the boundary between insert and plasmid vector with 
restriction enzyme analysis and the correct DNA-sequence was determined. EcN 
was transformed with these recombinant plasmids. 
 
4.2.2. Expression of HD5 in EcN and EcNc after cloning into pMUT1-Tc under 
the control of various promoters 
 Screening for expression of HD5 was performed by Western blot with a HD5 
antibody and a HD5 antiserum. First of all, the primary antibody was HD5 mouse 
monoclonal antibody (Hycult biotechnology, 1:100 dilution) and HRP-conjugated 
polyclonal rabbit anti-mouse serum was followed. However, expression of HD5 was 
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not detected by Western blot with them. We also tried to detect HD5 expression with 
other antiserums. HD5 rabbit polyclonal antiserum (provided by Edith Porter, 1:1,000 
dilution) was applied and HRP-conjugated polyclonal goat anti-rabbit serum was 
used as a secondary antiserum. Nevertheless, expression of HD5 could not be 
detected with any constructs by Western blot analysis using both HD5 mouse 
monoclonal antibody and HD5 rabbit polyclonal antiserum (data not presented). 
 
4.2.3. Cloning of nHD5 gene into low-copy number expression vectors for 
expression by the lactose promoter/operator system 
In a second approach the low-copy number expression vectors pCON3-86B, 
pCON7-71 and pCON7-74 were employed which utilize the lactose 
promoter/operator system and which permit the stable maintenance and regulated 
expression of highly toxic gene products (Anthony et al. 2004). nHD5 gene including 
the SD box was cloned between SalI and HindIII restriction enzyme sites of pCON3-
86B, pCON7-71 and pCON7-74 vectors and the resulting recombinant plasmids 
pCON86HD5, pCON71HD5 and pCON74HD5 introduced into E. coli K-12 BL21 by 
electroporation. Strain BL21 encodes the T7-DNA-depending RNA polymerase under 
the control of the lac promoter derivate L8-UV5 lac (Grossman et al. 1998, Pan and 
Malcolm 2000). nHD5 DNA sequence in all three recombinant plasmids was 
confirmed by restriction enzyme analysis and the preferred sequence was 
determined. 
 
4.2.4. Expression of HD5 in E. coli K-12 BL21 after cloning into low-copy 
number expression vectors under the control of the lactose 
promoter/operator system 
After induction for HD5 expression via the lactose promoter/operator system 
by 1 mM IPTG at 37 °C for 18 h of recombinant clones of BL21 harbouring 
pCON86HD5, pCON71HD5 and pCON74HD5, Western blot analysis was performed 
using HD5 rabbit polyclonal antiserum (provided by Edith Porter, 1:1000 dilution). 
However, HD5 expression could not be detected in any of BL21 strains harbouring  
recombinant plasmids (data not presented).  
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4.2.5. In vitro expression of nHD5 gene  
Since HD5 could not be expressed in any of the recombinant E. coli strains, 
we decided to attempt expression of HD5 in a cell free transcription/translation 
system using a ‘PUREexpress In Vitro Protein synthesis Kit (NEB)’. nHD5 gene 
which was synthesized commercially (Sloning Biotechnology) was used as the 
template for generation of LT_nHD5 DNA by two consecutive PCRs according to the 
manufacturer (Fig. 8). LT_nHD5 DNA was employed in protein synthesis and 
followed by Western blot analysis with HD5 rabbit polyclonal antiserum (provided by 
Edith Porter, 1:1,000 dilution).  
 
 
Fig. 8. Sequence of LT_nHD5 DNA. Generation of LT_nHD5 DNA for protein synthesis by cell free 
transcription/translation and three oligos used in the synthesis of LT_nHD5 (Table 5, Oligos 
PURERBSF1, PURER1 and PURET7F1 were used).  
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Fig. 9. Western blot analysis with HD5 rabbit polyclonal antiserum of expressed HD5 by cell free 
transcription/translation after incubation at 37 °C for 1 h. Lane 1: negative control DNA, 100 ng DNA 
was applied for protein synthesis, supplied by the manufacturer; Lane 2: LT_HD5, 100 ng DNA was 
applied for protein synthesis, 10.1 kDa; Lane 3: positive control, commercial mature HD5, 0.5 µg, 3.6 
kDa. 
 
 Western blot analysis showed expression of nHD5 DNA by “PUREexpress In 
Vitro Protein synthesis Kit”. This demonstrated nHD5 gene sequence to encode an 
expressible gene (Fig. 9). Synthesized HD5 protein (LT_HD5) is the proform of HD5 
with the theoretical MW of 10.1 kDa (Fig. 9, Lane 2) and commercial HD5 is the 
mature form and this theoretical MW is 3.6 kDa (Fig 9, Lane 3).  
 
4.2.6. Expression of nHD5 gene after cloning into pT7-vectors under control of 
the T7-RNA polymerase specific phi10 promotor  
In a third approach, high copy number vectors of the pT7 series were used as 
part of another expression vector system into which genes under the control of the 
T7-RNA-polymerase specific promoter phi10 can be cloned. With vector pT7-3, 
plasmid pT73HD5 was constructed with nHD5 gene including the SD box under the 
control of the phi10 promoter. As a negative control, nHD5 gene including the SD box 
was cloned into pT7-4 in antiparallel orientation to the phi10 promoter resulting in 
pT74HD5. Subsequently E. coli K-12 BL21, the E. coli strain with the T7 RNA 
polymerase in the chromosome under the control of the IPTG inducible lac promoter, 
was transformed with both recombinant constructs. The resulting strains, 
BL21T73HD5 and BL21T74HD5 were induced and subjected to SDS-PAGE and 
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subsequently Western blot analysis was performed with HD5 rabbit polyclonal 
antiserum (provided by Edith Porter, 1:1,000 dilution).   
 
 
Fig. 10. Western blot analysis with HD5 rabbit polyclonal antiserum of HD5 expressed in BL21 after 
induction at 37 °C for 4 h (Samples were pellet of whole cell proteins after centrifugation and adjusted 
to cell density (1.5x10
8 
cfu cells were loaded for each lane)). Lane 1: BL21; Lane 2: BL21T73HD5, The 
theoretical MW of expressed HD5 is 10.1 kDa; Lane 3: negative control, BL21T74HD5; Lane 4: 
positive control, commercial mature HD5, 3.6 kDa, 1 µg.   
 
Western blot analysis demonstrated the expression of the proform of HD5 
(theoretical MW: 10.1 kDa) in E. coli K-12 BL21 harbouring recombinant pT7-3 with 
nHD5 gene including SD box (BL21T73HD5) in contrast to the corresponding strain 
with the recombinant pT7-4 plasmid (BL21pT74HD5: negative control) (Fig. 10).   
 
4.2.7. Expression of HD5 and HBD2 fusion proteins in EcN and EcNc after 
cloning into pET-28a(+) vector carrying a His tag and under the control of 
the T7-RNA polymerase 
Plasmid vector pET-28a(+) (Novagen, USA, Fig. 11), which encodes two His 
tags and allows expression of genes under the control of the T7 promoter was used 
for the construction of recombinant plasmids coding for fusion proteins consisting of 
an N-terminal His tag and a defensin. The synthetic full-length nHBD2-gene or that 
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part of nHBD2-gene encoding the mature part of HBD2 (nMHBD2: amino acids G24 
to P64, Fig. 3 A) was ligated with the cleaved pET-28a(+) to construct the expression 
plasmids pEAS101 and pEAS102, respectively (Figs. 12, 13). Plasmid pEAS101 
harbors nHBD2- and pEAS102 encodes nMHBD2-gene. Both genes were under the 
control of the T7 promoter and each of the resulting defensins (HisHBD2, 
HisMHBD2) contained an N-terminal His-tag. Plasmids pEAS103 and pEAS104 were 
constructed in order to express both the proform of HD5 and the mature part of HD5 
(nMHD5: amino acids A63 to R94, Fig. 3 B), respectively. Again, the resulting 
defensin proteins contained an N-terminal His-tag. The gene product encoded by 
pEAS103 was HisHD5, and the one encoded by pEAS104 was HisMHD5 (Figs. 14, 
15).  
 
 
Fig. 11. Expression vector pET-28a(+). (A) Physical map of vector pET-28a(+) harboring the gene 
(open arrow in A) encoding the protein depicted in. (B) Schematic composition of the protein encoded 
by vector pET-28a(+).  
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Fig. 12. Expression plasmid pEAS101. (A) Physical map of the recombinant plasmid pEAS101 
encoding the fusion gene composed of the fusion partner including a His-tag and nHBD2-gene. (B) 
Schematic composition of the fusion protein HisHBD2. 
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Fig. 13. Expression plasmid pEAS102. (A) Physical map of the recombinant plasmid pEAS102 
harboring the fusion gene composed of the fusion partner including a His-tag and that part of nHBD2-
gene encoding the mature form of HBD2. (B) Schematic composition of the fusion protein HisMHBD2. 
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Fig. 14. Expression plasmid pEAS103. (A) Physical map of pEAS103 containing the fusion gene 
composed of the fusion partner with a His-tag and nHD5-gene. (B) Physical map of the composition of 
the fusion protein HisHD5. 
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Fig. 15. Expression plasmid pEAS104. (A) Physical map of the recombinant plasmid pEAS104 
encoding the fusion gene composed of the fusion partner encoding a His-tag and that part of nHD5-
gene encoding mature HD5. (B) Fusion protein HisMHD5 and the parts it is composed of. 
 
4.3. Expression of HBD2 and HD5 fusion proteins in Escherichia coli 
Western blot analysis of whole cellular protein of the induced recombinant 
strains EcN100, EcN101 and EcN102 was performed with anti-HBD2 rabbit 
polyclonal antiserum for detection of HisHBD2 and HisMHBD2 expression. After cell 
lysis, also soluble and insoluble protein fractions were screened by Western blot 
analysis with HBD2 rabbit polyclonal antiserum. The negative control, EcN100, was 
always treated like EcN101 and EcN102 with respect to growth, induction, sample 
preparation, SDS-Page and Western blot.   
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Fig. 16. (A) Western blot analysis with anti-HBD2 rabbit polyclonal antiserum of whole cell proteins 
after induction of expression at 20 °C for 6 h (Samples were pellet of whole cell proteins after 
centrifugation and adjusted to cell density (1.5x10
8 
cfu cells were loaded for each lane)). Lane 1: 
EcN100, Lane 2: EcN101. (B) Western blot analysis with anti-HBD2 rabbit polyclonal antiserum of 
soluble and insoluble forms of HisHBD2 expressed in EcN101 after induction at 20 °C for 6 h 
(Samples were adjusted to the number of bacterial cells (1.5x10
8 
cfu)). Lane 1: supernatant of whole 
cell proteins after cell lysis and centrifugation and filtration (i.e. soluble protein fraction); Lane 2:  pellet 
of whole cell proteins after cell lysis and centrifugation (i.e. insoluble protein fraction). 
 
 
Fig. 17. (A) Western blot analysis with anti-HBD2 rabbit polyclonal antiserum of whole cell proteins 
after induction of expression at 37 °C (Samples were adjusted to the number of bacterial cells (1.5x10
8 
cfu)). Lane 1: EcN100, pellet of whole cell proteins after centrifugation; Lane 2: EcN100, cell-free 
culture medium after centrifugation and filtration; Lane 3: EcN102, pellet of whole cell proteins after 
centrifugation; Lane 4: EcN102, cell-free culture medium after centrifugation and filtration; Lane 5: 
positive control (commercial HBD2, 1 µg). (B) Western blot analysis with anti-HBD2 rabbit polyclonal 
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antiserum of soluble and insoluble forms of HisMHBD2 expressed in EcN102 after induction at 37 °C 
for 2 h (Samples were adjusted to the number of bacterial cells (1.5x10
8 
cfu)). Lane 1: supernatant of 
whole cell proteins after cell lysis and centrifugation and filtration (i.e. soluble protein fraction); Lane 2: 
pellet of whole cell proteins after cell lysis and centrifugation (i.e. insoluble protein fraction). 
 
HisHBD2 expression was assayed at several time points after induction at 
37°C, because in the clinical setting, after oral administration of the defensin-
producing EcN strain, defensin expression should take place in the human gut at the 
physiological body temperature. However, HisHBD2 was not detected after induction 
at 37 °C at any time point (data not shown). HisHBD2 was observed after induction at 
20 °C for 6 h and present in the insoluble pellet of whole cell proteins (Fig. 16). In 
contrast, after induction of HisMHBD2 expression at 37 °C for 2 h, HisMHBD2 was 
detected in the supernatant (soluble protein fraction) as well as in the pellet (insoluble 
protein fraction) after cell lysis (Fig. 17). No defensin protein was detected in 
corresponding samples of the negative control (EcN100).   
Expression of HisHD5 and HisMHD5 in EcN103 and EcN104 was screened by 
Western blot with HD5-specific rabbit polyclonal antiserum of whole cell protein and 
soluble as well as insoluble protein fraction.  
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Fig. 18. (A) Silver-stained gel after SDS-PAGE (the boxes indicate expressed HisHD5) and (B) 
Western blot analysis with anti-HD5 rabbit polyclonal antiserum of whole cell proteins after induction of 
expression at 37 °C for 4 h (Samples were pellet of whole cell proteins after centrifugation, and 
identical optical densities (corresponding to1.5x10
8 
cfu) were loaded for each lane). Lane 1: EcN1219, 
Lane 2: EcN100, Lane 3: EcN103, Lane 4: EcNc1219, Lane 5: EcNc100, Lane 6: EcNc103, Lane 7: 
positive control (commercial HD5, 1 µg). (C) Western blot analysis with anti-HD5 rabbit polyclonal 
antiserum of soluble and insoluble forms of HisHD5 expressed in EcN103 after induction at 37 °C for 4 
h (Samples were adjusted to the number of bacterial cells (1.5x10
8 
cfu)). Lane 1: supernatant of whole 
cell proteins after cell lysis and centrifugation and filtration (i.e. the soluble protein fraction); Lane 2: 
pellet of whole cell proteins after cell lysis and centrifugation (i.e. the insoluble protein fraction). 
 
 
Fig. 19. Western blot analysis with anti-HD5 rabbit polyclonal antiserum of whole cell proteins after 
induction at 37 °C (Samples were adjusted to the number of bacterial cells (1.5x10
8 
cfu)). Lane 1: 
EcN100, pellet of whole cell proteins after centrifugation; Lane 2: EcN100, cell-free culture medium 
after centrifugation and filtration; Lane 3: EcN104, pellet of whole cell proteins after centrifugation; 
Lane 4: EcN104, cell-free culture medium after centrifugation and filtration.  
 
HisHD5 was detected after induction at 37 °C for 4 h, however, it was present 
in the insoluble fraction of total cellular proteins (Fig. 18). HisMHD5 was detected as 
well, but only a very low amount of HisMHD5 was produced after induction at 37 °C 
for 1 h and 2 h (Fig. 19). HisMHD5 was not detectable at all after induction at 37 °C 
for more than 2 h in the presence of the protease inhibitor cocktail (data not shown). 
 
4.4. Isolation by nickel-affinity chromatography and antimicrobial activity of 
HisMHBD2  
 HisMHBD2 fusion protein expressed in EcN103 was eluted from Ni-column 
and subsequently dialysis and protein quantification were performed as described in 
Materials and Methods. The resulting material used for antimicrobial activity tests. Ni-
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column eluates from EcN100 samples (negative control) were treated like eluates 
from HisMHBD2 samples. Antimicrobial activity of eluted proteins was evaluated by 
radial diffusion assays employing E. coli K-12 MG1655, Salmonella enterica serovar 
Typhimurium SL1344 and Listeria monocytogenes EGD as indicator strains. 
 
 
 
Fig. 20. The antimicrobial activity of HisMHBD2 against E. coli K-12 MG1655. 1: negative control 
(EcN100), 4 µg of fraction 0.03 eluted from Ni-column; 2: eluted proteins including HisMHBD2 
(EcN102), 4 µg of fraction 0.03 eluted from Ni-column; 3: positive control, commercial HBD2, 1 µg; 
The lines indicate the 5 mm diameters of wells, Experiments were carried out in triplicates and the 
mean values and standard deviations are presented. 
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Fig. 21. The antimicrobial activity of HisMHBD2 against Salmonella enterica serovar Typhimurium 
SL1344. 1: negative control (EcN100), 4 µg of fraction 0.03 eluted from Ni-column; 2: eluted proteins 
including HisMHBD2 (EcN102), 4 µg of fraction 0.03 eluted from Ni-column; 3: positive control, 
commercial HBD2, 1 µg; The lines indicate the 5 mm diameters of wells, Experiments were carried out 
in triplicates and the mean values and standard deviations are presented. 
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Fig. 22. The antimicrobial activity of HisMHBD2 against Listeria monocytogenes EGD. 1: negative 
control (EcN100), 4 µg of fraction 0.03 eluted from Ni-column; 2: eluted proteins including HisMHBD2 
(EcN102), 4 µg of fraction 0.03 eluted from Ni-column; 3: positive control, commercial HBD2, 1 µg; 
The lines indicate the 5 mm diameters of wells, Experiments were carried out in triplicates and the 
mean values and standard deviations are presented. 
 
Inhibition zones could be detected with eluted proteins from strain EcN102 
encoding HisMHBD2 and HBD2 (the positive control) while the negative control 
(eluted protein from EcN100) did not show any antimicrobial effect (Figs. 20-22). 
Insoluble HisHBD2 from EcN101 and HisHD5 encoded by EcN103 were 
examined for bioactivity after the refolding procedure by “Protein Refolding kit” 
(Novagen, USA), however, these protein fractions did not show any activity. 
HisMHD5 from EcN104 was expressed at a very low yield in the presence of the 
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protease inhibitor cocktail. Therefore it was not possible to obtain enough material to 
get a solution of comparable concentration for activity tests.  
 
4.5. Secretion of a MHBD2 fusion protein by recombinant E. coli strains 
E. coli protein YebF (10.8 kDa) is a soluble endogenous protein secreted into 
the medium and it is used as a carrier for transgenic proteins (Zhang et al. 2006). It 
has been shown that passenger proteins linked to the carboxyl end of YebF are 
efficiently secreted by the respective recombinant E. coli K-12 strain. Therefore, we 
decided to design a fusion protein consisting of the mature part of HBD2 fused to the 
C-terminus of YebF in order to achieve secretion of the resulting fusion protein 
YebFMHBD2 by the respective recombinant E. coli strains (Figs. 23, 25). EcN105 
harbouring plasmids pAR1219 and pEAS105 encoding only yebF (NCBI (B1847)) 
was used as the negative control and treated as the recombinant strain encoding a 
defensin gene (Fig. 24). 
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Fig. 23. DNA and amino acid sequences of the constructed fusion gene and the corresponding fusion 
protein YebFMHBD2; Lane 1: cDNA sequence of yebFMHBD2-gene; Lane 2: sequence of 
corresponding amino acids of YebFMHBD2. 
 
 
Fig. 24. Expression plasmid pEAS105. (A) Physical map of plasmid pEAS105 harboring yebF gene. 
(B) Schematic presentation of the corresponding protein YebF. 
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Fig. 25. Expression plasmid pEAS106. (A) Physical map of the recombinant plasmid pEAS106 
encoding the fusion gene composed of the fusion partner, yebF and nMHBD2-gene. (B) Schematic 
composition of the fusion protein YebFMHBD2. 
 
Secretion of YebFMHBD2 was tested by analysis of whole cellular protein and 
cell-free supernatant samples of induced EcN105 and EcN106 by Western blot. 
Since the presence of the fusion protein in the culture medium could be a result of 
the achieved secretion via YebF, cell lysis, leakage through the outer membrane, a 
natural cell secretion process, or some combination thereof, we analyzed cells and 
growth medium by Western blot analysis, not only with anti-HBD2 rabbit polyclonal 
antiserum, but also with a monoclonal antibody specific for the cytoplasmic ß-
galactosidase and with a rabbit polyclonal antiserum specific for the periplasmic 
maltose-binding protein (MBP) (Fig. 26). 
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Fig. 26. Analysis of intracellular and secreted polypeptides from recombinant strains EcN105 and 
EcN106 (Samples were adjusted to the number of bacterial cells (1.1x10
8 
cfu)). Lane 1: EcN105, 
cellular proteins (pellet after centrifugation); Lane 2: EcN105, proteins in the cell-free supernatant 
(supernatant after centrifugation and filtration); Lane 3: EcN106, cellular proteins (pellet after 
centrifugation); Lane 4: EcN106, proteins in the cell-free supernatant (supernatant after centrifugation 
and filtration). 
 
YebFMHBD2 was found in the cell-free supernatant after centrifugation and 
sterile filtration of induced EcN106 cultures, in contrast to EcN105 cultures. Fig. 26 
shows the accumulation of YebFMHBD2 in the medium during induction. In the cell- 
free supernatant, YebFMHBD2 was clearly detected at 2 h and 4 h after induction. 
After induction for 20 h, most of YebFMHBD2 was present in the medium. Two 
protein bands appeared at this time point, the reason might be protein degradation. 
In samples representing the bacterial cells, ß-galactosidase, MBP and HBD2 were 
readily detected. ß-galactosidase, however, was not observed in the medium at all at 
any time point analyzed. MBP was not detected in the medium at 1.5 h after 
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induction. A trace amount of MBP was detected in the medium at 3 h and 6 h after 
induction, which indicates the beginning of some inevitable cell lysis. 
Moreover, the location of synthesized YebFMHBD2 from EcN106 was 
compared with the location of HisMHBD2 from EcN102 by Western blot analysis (Fig. 
27).  
 
Fig. 27. Comparison of intracellular and secreted polypeptides from recombinant strains of EcN102 
encoding HisMHBD2 and EcN106 encoding YebFMHBD2 at 2 h after induction by Western blot 
(Samples were adjusted to the number of bacterial cells (1.1x10
8 
cfu)). Lane 1: EcN100, cellular 
proteins (pellet after centrifugation); Lane 2: EcN100, proteins in the cell-free supernatant (supernatant 
after centrifugation and filtration); Lane 3: EcN102, cellular proteins (pellet after centrifugation); Lane 
4: EcN102, proteins in the cell-free supernatant (supernatant after centrifugation and filtration); Lane 5: 
EcN106, cellular proteins (pellet after centrifugation); Lane 6: EcN106, proteins in the cell-free 
supernatant (supernatant after centrifugation and filtration);  Lane 7: positive control, commercial 
HBD2, 1 µg, The theoretical molecular masses are: for HisMHBD2 8.2 kDa, for YebFMHBD2 with 
signal peptide 17.3 kDa, secreted YebFMHBD2 without signal peptide 15.1 kDa and for mature HBD2 
4.3 kDa. 
 
 YebFMHBD2 was detected in bacterial cells and in the culture medium, 
whereas HisMHBD2 was present only in the fraction representing total cellular 
proteins and not in the cell-free supernatant (i.e. culture medium). The fusion 
defensins were observed to migrate slower than expected from their theoretical 
molecular mass (HisMHBD2: 8.2 kDa, YebFMHBD2 with signal peptide: 17.3 kDa, 
secreted YebFMHBD2 without signal peptide: 15.1 kDa) in Western blot analysis (Fig. 
27). Small peptides often fail to follow the standard relationship between mass and 
mobility in SDS-PAGE (Faurschou et al. 2005, Huang and Matthews 1990, Weber et 
al. 1972). Moreover, secreted YebFMHBD2 from the spent culture medium (Fig. 27. 
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Lane 6) was detected as a smaller protein than YebFMHBD2 from the cellular protein 
pool (Fig. 27. Lane 5), because YebF is cleaved after the 21-amino acid sec-leader 
during secretion process (Zhang et al. 2006).  
These results demonstrate YebFMHBD2 to be secreted into the medium and 
not just being released by cell lysis. 
 
4.6. Antimicrobial activity of the secreted fusion protein YebFMHBD2  
 Firstly, YebFMHBD2 encoded by EcN106 was tested for antimicrobial activity 
by radial diffusion assays. However, inhibition zones were observed with the negative 
control, secreted proteins from EcN105. The reason could be that EcN produces and 
secretes the two microcins M and H47 (Patzer et al. 2003). 
Therefore, to test for antimicrobial activity of the secreted YebFMHBD2 protein 
supernatants of the microcin-negative isogenic SK22D strain harboring pAR1219 and 
pEAS106 were employed. Cell-free supernatants of induced cultures from SK22D105 
and SK22D106 were obtained by centrifugation and sterile-filtration. Before 
antimicrobial tests by radial diffusion assays and killing assays in liquid medium were 
performed, the respective cell-free supernatant was dialyzed and concentrated.   
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Fig. 28. The antimicrobial activity of YebFMHBD2 by radial diffusion tests with E. coli K-12 MG1655. 1: 
negative control, proteins in the cell free supernatant after centrifugation and filtration from SK22D105, 
4 µg; 2: proteins in the cell free supernatant including YebFMHBD2 after centrifugation and filtration 
from SK22D106, 4 µg; 3: positive control, commercial HBD2, 1 µg; The lines indicate the 5 mm 
diameters of wells, Experiments were carried out in triplicates and the mean values and standard 
deviations are presented. 
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Fig. 29. The antimicrobial activity of YebFMHBD2 by radial diffusion tests with Salmonella enterica 
serovar Typhimurium SL1344, 1: negative control, proteins in the cell free supernatant after 
centrifugation and filtration from SK22D105, 4 µg; 2: proteins in the cell free supernatant including 
YebFMHBD2 after centrifugation and filtration from SK22D106, 4 µg; 3: positive control, commercial 
HBD2, 1 µg; The lines indicate the 5 mm diameters of wells, Experiments were carried out in 
triplicates and the mean values and standard deviations are presented. 
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Fig. 30. The antimicrobial activity of YebFMHBD2 by radial diffusion tests with Listeria monocytogenes 
EGD. 1: negative control, proteins in the cell free supernatant after centrifugation and filtration from 
SK22D105, 4 µg; 2: proteins in the cell free supernatant including YebFMHBD2 after centrifugation 
and filtration from SK22D106, 4 µg; 3: positive control, commercial HBD2, 1 µg; The lines indicate the 
5 mm diameters of wells, Experiments were carried out in triplicates and the mean values and 
standard deviations are presented. 
 
 
 
 
 
 
81 
 
 
Fig. 31. Antimicrobial activity of secreted proteins from SK22D105 (negative control) and secreted 
proteins including YebFMHBD2 from SK22D106 against E. coli K-12 MG1655 as determined by killing 
assays in liquid medium. Experiments were carried out in triplicates and the mean values and 
standard deviations are presented. 
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Fig. 32. Antimicrobial activity of secreted proteins from SK22D105 (negative control) and secreted 
proteins including YebFMHBD2 from SK22D106 against Listeria monocytogenes EGD as determined 
by killing assays in liquid medium. Experiments were carried out in triplicates and the mean values 
and standard deviations are presented. 
 
Only supernatant from SK22D106 showed killing of E. coli K-12 MG1655, 
Salmonella enterica serovar Typhimurium SL1344 and Listeria monocytogenes EGD 
in radial diffusion assays (Figs. 28-30). The same supernatant caused growth 
inhibition of E. coli K-12 MG1655 and Listeria monocytogenes EGD in liquid culture 
(Figs. 31, 32). Since the killing assay in liquid culture was performed in the presence 
of only 1 % TSB medium, E. coli K-12 MG1655 growth was also reduced in the 
presence of the negative control (secreted proteins from SK22D105) after 4 h 
incubation. 
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5. Discussion 
 
This study was undertaken to do the first step in the development of a 
microbial delivery vector for defensins using a well-known probiotic E. coli strain,      
E. coli Nissle 1917 (EcN) (Sonnenborn and Schulze 2009). We have chosen EcN 
because this probiotic has an excellent biosafety profile and is used in medical 
practice since 1917. Moreover, it is marketed as a licensed drug in 8 European 
countries as well as in Iran, Lebanon, Peru and South Korea. 
 
5.1.  Construction and expression of cationic antimicrobial peptides, i.e. 
defensins in E. coli 
To achieve expression of small cationic peptides with antibacterial activity in 
bacteria, two major barriers must be overcome. These include the potential ability of 
the cationic peptides to kill the producing strain and the susceptibility of the cationic 
peptides to proteolytic degradation. Piers and coworkers found that they could 
overcome such barriers by using a fusion protein expression system (Piers et al. 
1993).  
Efficient expression of defensin genes in E. coli is not achieved with the 
original DNA sequence, because of different codon usage in humans and in E. coli. 
Therefore, the defensin genes to be cloned were optimized for expression in E. coli. 
It was shown that codon optimization can significantly improve the expression level. 
About nine-fold improvement of cellular soluble HBD2 expression was observed by 
optimizing the HBD2 gene with E. coli-preferred codons, as reported by Peng and co-
workers (Peng et al. 2004). Therefore, two new sequences encoding human beta-
defensin 2 (nHBD2) and human alpha-defensin 5 (nHD5) were synthesized with the 
codon-preference of E. coli. 
In this study, the first defensin to be cloned and produced in EcN was human 
alpha-defensin 5 (HD5), which together with human alpha-defensin 6 is specifically 
reduced in small intestinal Crohn’s disease (Wehkamp and Stange 2010). We have 
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chosen HD5 because it is encoded as an inactive proform and production of the 
inactive proform of HD5 should not affect viability of EcN. The other defensin 
selected for production by EcN was HBD2. This defensin is induced in Caco-2 cells 
by EcN via its flagellin and its induction in Crohn’s colitis is typically impaired 
(Gersemann et al. 2008, Schlee et al. 2007). 
In a first approach, we tried to express human α-defensin 5 (HD5) after cloning 
the optimized gene in pMUT1-Tc, which is a derivate of the very stable cryptic 
plasmid pMUT1 of EcN. The recombinant plasmid constructs designed harboured the 
HD5 gene under the control of one of several promoters such as nirB, bla, lac and 
acrB. nirB promoter is active under anaerobic condition and bla promoter is a 
constitutive one. And lac promoter is inducible by IPTG and acrB promoter is 
expressed under stress conditions. Since pMUT1 is the very stable cryptic plasmid of 
WT EcN and several promoters employed in this study in order to control of 
expression of HD5 into pMUT1-Tc might be suitable for production of defensins in the 
human gut condition, we decided to attempt to construct recombinant plasmids with 
this plasmid and these promoters. Moreover, the low-copy number expression 
vectors pCON3-86B, pCON7-71 and pCON7-74 were applied which utilize the 
lactose promoter/operator system and allow the stable maintenance and regulated 
expression of highly toxic gene products (Anthony et al. 2004). HD5 expression was 
induced by adding 1.0 mM IPTG to the grown culture at OD600 of 1.0 and culture was 
incubated at 37 °C for 18 h. However, expression of the target defensin was not 
detected with these constructs by Western blot. The promoters applied might not be 
proper to produce HD5. It was reported that the many different types of promoters 
can affect the level of gene expression in E. coli. The suitability of promoters for high 
level gene expression is governed by several criteria. First, the promoter must be 
strong, capable of protein production in excess of 10-30 % of the total cellular protein. 
Second, the promoter should exhibit a minimal level of basal transcription; a highly 
repressible promoter is particularly important for cases in which the protein of interest 
is toxic or detrimental to the growth of the host cell. Third, promoters should be 
capable of induction gene (Hannig and Makrides 1998). Besides, the strength of 
different promoters is determined by the relative frequency of transcription initiation. 
This is mainly affected by the affinity of the promoter sequence for RNA polymerase 
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(Tegel et al. 2011). Since several promoters which we tried do not meet all criteria for 
high level gene expression in E. coli, a yield of expression of the target protein might 
not be enough to be detected via Western blot analysis.   
Many promoter systems of E. coli are described as tools for protein 
expression, but only a few of them are commonly used (Table 7). The expression 
system based on T7 RNA polymerase promoter was employed in this study which 
allowed expression of HD5 is the most powerful according to Terpe (Terpe 2006). 
The preferential codon optimized HD5 (nHD5) gene was checked for 
expression in a cell free transcription/translation system under the control of the T7 
RNA polymerase promoter using “PURExpress In Vitro Protein synthesis Kit (NEB)”. 
The result showed that the gene sequence encodes an expressible gene. 
Since we confirmed that nHD5 gene was able to be expressed under the 
control of the T7-RNA-polymerase, in a second approach high copy number vectors 
of the pT7 series were used as another expression vector system into which genes 
under the control of the T7-RNA-polymerase can be cloned. This approach was 
successful and expression of the proform of HD5 in E. coli K-12 BL21 harbouring 
recombinant pT7-3 with the nHD5 gene by Western blot could be demonstrated.  
This expression system is one of the most widely used ones in E. coli (Studier 
and Moffatt 1986). The T7-RNA-polymerase is very selective and efficient, resulting 
both in a high frequency of transcription initiation and effective elongation. These 
features result in a RNA elongation that is approximately five-fold faster than for       
E. coli RNA polymerase; hence, the T7 promoter is a much stronger promoter than   
E. coli promoters (Golomb and Chamberlin 1974). The T7-RNA-polymerase that is 
able to bind and start transcription from the phi10 promoter from bacteriophage T7. 
This promoter is present in the plasmid vectors pT7-3 and pT7-4 employed in this 
study. 
 The combination of the IPTG-inducible T7-polymerase gene and the gene of 
interest cloned in pT7-3 or pT7-4 under the control of the phi10 promoter results in 
high level protein expression. However, as reported by Tegel et al. the fraction of 
soluble protein is rather small in contrast to the expression by the very weak 
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promoter lacUV5, which results in very low protein amounts but with the largest 
fraction of soluble protein (Tegel et al. 2011).  
According to our study, defensin genes may be necessary to be under the 
control of the promoter resulting in high protein yields. 
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Table 7. E. coli promoter systems that are in use for heterologous protein production and their characteristics (modified from Terpe 2006). 
Expression system 
based on 
Induction (range of inducer) Level of expression Key features Original reference 
lac promoter 
Addition of IPTG 0.2 mM 
(0.05~2.0 mM) 
Low level up to middle 
Weak, regulated suitable for gene products at 
very low intracellular level 
Comparatively expensive induction 
(Gronenborn 1976) 
trc and tac promoter 
Addition of IPTG 0.2 mM 
(0.05~2.0 mM) 
Moderately high 
High-level, but lower than T7 system regulated 
expression 
Comparatively expensive induction 
High basal level 
(Brosius et al. 
1985) 
T7 RNA polymerase 
Addition of IPTG 0.2 mM 
(0.05~2.0 mM) 
Very high 
Utilizes T7 RNA polymerase 
High-level inducible over expression 
T7lac system for tight control of induction 
needed for toxic clones 
Relatively expensive induction 
Basal level depends on used strain (pLys)  
(Studier and Moffatt 
1986) 
Phage promoter PL 
Shifting the temperature from 
30 to 42 °C (45 °C) 
Moderately high 
Temperature-sensitive host required  
Less likelihood of “leaky” uninduced expression 
Basal level, high basal level by temperatures 
below 30°C 
No inducer 
(Elvin et al. 1990) 
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tetA 
promoter/operator 
Anhydrotetracycline 200 µg/l 
Variable from middle to 
high level 
Tight regulation  
Independent on metabolic state 
Independent on E. coli strain 
Relative in expensive inducer 
Low basal level 
(Skerra 1994) 
araBAD promoter 
(PBAD) 
Addition of L-arabinose 0.2 %  
(0.001-1.0 %) 
Variable from low to high 
level 
Can fine-tune expression levels in a dose-
dependent manner 
Tight regulation possible 
Low basal level 
Inexpensive inducer 
(Guzman et al. 
1995) 
rhaPBAD promoter L-rhamnose 0.2 % 
Variable from low to high 
level 
Tight regulation 
Low basal activity 
Relative expensive inducer 
(Haldimann et al. 
1998) 
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Therefore, we made use of the low copy number vector, pET-28a(+) 
expression vector, for cloning defensin genes. The defensin gene was ligated in this 
vector in a way that gives rise to a fusion gene encoding a protein consisting of an N-
terminal peptide harboring a His-tag and the defensin. In addition, the cloning of the 
respective defensin gene was performed in a way that allowed the expression of the 
fusion gene under the control of the phi10 T7-polymerase-specific promoter. The T7 
polymerase gene, the expression of which is IPTG-inducible, was provided by 
plasmid pAR1219. Both plasmids, pAR1219 and the recombinant pET-28a(+), were 
introduced into WT EcN and the EcN strain EcNc cured of both of its cryptic plasmids 
pMUT1 and pMUT2. To reduce the risk of killing the producer strain of the His-tagged 
defensin induction of expression was performed in Turbo medium containing 86 mM 
NaCl. As reported by Xu and colleagues (Xu et al. 2006), this concentration of NaCl 
led to the survival of 80 % of an E. coli D31 culture producing HBD2, in contrast to 
only 40 % survival in a culture without NaCl. In our hands, these measures helped 
the recombinant EcN strains to grow even during expression of the recombinant 
defensin proteins.  
Another potential problem, defensin degradation, was avoided by adding a 
protease inhibitor cocktail during incubation. A further approach to impede protein 
degradation in the absence of a protease inhibitor cocktail is the deletion of genes 
encoding proteases such as OmpT and Lon in EcN to construct a suitable strain for 
protein expression comparable to E. coli K-12 strains BL21 (DE3) and KRX (Derbise 
et al. 2003). This will be part of the ongoing work to optimize defensin production by 
EcN.  
Western blots demonstrated successful expression of HBD2 and HD5 as 
fusion proteins with a His-tag at the N terminus in probiotic EcN under the control of 
the T7 promoter. The recombinant EcN strains harbored the recombinant plasmid 
pET-28a(+) and the T7-polymerase encoding plasmid pAR1219. The full-length 
HBD2 fusion protein (HisHBD2) was mainly present in the insoluble protein fraction, 
but the fusion protein containing the mature part of HBD2 (HisMHBD2) was detected 
in the soluble and insoluble protein fraction. This is in accordance with an earlier 
study showing mature HBD2 without signal peptide to have a higher solubility than 
full-length HBD2 (Xu et al. 2006).  
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This is the consequence of the presence of the signal peptide being rich in 
hydrophobic amino acids (78.3 %) in comparison with the mature part of HBD2 
(34.1 %). The high hydrophobicity of the signal peptide resulted in the lower solubility 
of HisHBD2 protein, because the exposure of the hydrophobic part might induce the 
aggregation. The signal peptide might also reduce the folding rate or accuracy of 
disulfide bonds in that part of the molecule representing mature HBD2.  
The proform of HD5 fusion protein (HisHD5) consisting besides the part of the 
fusion partner with the His tag of the HD5 signal sequence, of the propiece and of the 
piece representing the mature HD5, was found only in the insoluble protein fraction 
without showing bioactivity. Only very low amount of the fusion protein with the 
mature HD5 (HisMHD5) could be detected in EcN. Since the signal peptide of HD5 
also contains a high percentage of hydrophobic amino acids (78.9 %), this might be 
the cause for the insolubility of HisHD5. Production of the recombinant mature forms 
of α-defensins is considered challenging, since the presence of an anionic pre-piece 
is believed to be important for the inhibition of cytotoxicity of the cationic peptides 
(Valore et al. 1996). It was reported that the expression of several human alpha-
defensins (hNP-1, hNP-2, hNP-3, hD-5 and hD-6) in bacteria as mature fusion 
defensins containing a portion of the tryptophan operon of E. coli including a His tag 
(111 AA) did not result in soluble proteins, since they  were mainly found in inclusion 
bodies (Pazgier and Lubkowski 2006).  
Moreover, α-defensins could be produced only with low yields by engineered 
bacterial systems, and α-defensins were sensitive to rapid degradation by bacterial 
proteases (Piers et al. 1993, Valore and Ganz 1997). Up to now, successful 
expression of human alpha-defensins in soluble and active form in E. coli has not 
been reported.  
 
5.2. Antimicrobial activity of expressed fusion mature HBD2 (HisMHBD2)  
In this study, mature fusion HBD2 (HisMHBD2) was produced in a soluble 
form. It is well-known that soluble recombinant proteins are often correctly folded and 
are usually bioactive (Sorensen H. P. and Mortensen 2005). Therefore, the 
heterologous expression in bacteria resulting in a soluble protein is very attractive. In 
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fact, the soluble HisMHBD2 obtained in this study showed antimicrobial activity in 
radial diffusion assays against E. coli K-12 MG1655, Salmonella enterica serovar 
Typhimurium SL1344 and Listeria monocytogenes EGD. According to the 
antimicrobial mechanism of action of defensins, cationic parts of the peptides are 
capable of interacting with negatively charged structures of the bacterial membrane 
and then lead to its permeabilization (Ganz 1999, Peschel 2002). HisMHBD2 is 
cationic containing the fusion partner (pI 8.0), therefore, even the fusion protein 
HisMHBD2 seems to be able to interact with the cell membranes of microbes. 
However, as other modes of defensin action are discussed, we cannot exclude other 
mechanisms of antimicrobial activity exhibited by HisMHBD2 (Yount et al. 2009).   
 
5.3.  Secretion of a MHBD2 fusion protein by recombinant E. coli strains 
Although leakage or lysis of EcN bacteria in the human gut might occur and 
could be sufficient to release HBD2 in significant amounts we constructed a 
recombinant EcN stain encoding a fusion protein consisting of YebF and the mature 
part of HBD2, in order to achieve secretion of YebFMHBD2 product.  The carrier 
protein YebF was used as the fusion partner since “passenger” proteins linked to the 
C-terminus of YebF were reported to be efficiently secreted from E. coli K-12 strains 
(Zhang et al. 2006). As expected, secretion of YebFMHBD2 from recombinant EcN 
strains could be demonstrated and we could show that the appearance of this fusion 
protein in the cell-free supernatant was not due to cell lysis at early time points. 
Occurrence of cell leakage/lysis was checked by Western blots specific for the 
cytoplasmic ß-galactosidase and the periplasmatic maltose-binding protein in 
samples from bacterial cell extracts and samples from the cell-free culture 
supernatants. The results obtained with YebF resembled closely those reported in 
the publication by Zhang and colleagues (Zhang et al. 2006). They compared the 
release of YebF and maltose-binding protein (MBP).  
In their study, YebF was present in the culture medium at 1.5 h and 3 h after 
induction, whereas MBP was not present in the medium at 1.5 h and was hardly 
detected in the medium at 3 h after induction. After induction for 6 h, MBP was 
primarily localized in the cellular fraction, although some leakage into the culture 
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medium was observed. In contrast, YebF was almost entirely present in the culture 
medium at 6 h after induction. The authors believed that these data support YebF to 
be secreted rather than leaking across the outer membrane. We achieved 
comparable results for the location of MBP. Moreover, we observed that 
YebFMHBD2 was present in the culture medium at 2 h and 4 h after induction, and 
its main amount was present in the medium at 20 h after induction. In addition, the 
location of cytoplasmic ß-galactosidase protein was analyzed in our study, and this 
protein was only detected in the cell fraction but not in the medium. Moreover, in 
comparison to the location of YebFMHBD2, HisMHBD2 was only present in the cells 
at 2 h after induction, whereas YebFMHBD2 was present at this time point in the 
cells and in the culture medium as well. These results demonstrated that fusion of 
MHBD2 to the C-terminus of YebF led to efficient secretion of the fusion protein from 
the producing bacterial cells.  
 
5.4. Antimicrobial activity of secreted YebF-mature HBD2 fusion protein 
(YebFMHBD2) 
Interestingly, cell-free supernatant samples from bacterial cultures expressing 
YebFMHBD2 had antimicrobial activity. Such samples in contrast to control samples 
of cultures expressing only YebF inhibited growth of the Gram-negative strains E. coli 
K-12 MG1655 and Salmonella enterica serovar Typhimurium SL1344 as well as of 
the Gram-positive Listeria monocytogenes strain EGD. Since secreted YebFMHBD2 
without signal peptide is cationic including the fusion partner (theoretical pI 8.93), 
thus, the fusion protein YebFMHBD2 is assumed to interact against negatively 
charged structures of the bacterial membrane. Obviously, at least part of the 
YebFMHBD2 protein becomes folded after secretion in a way that allows the 
MHBD2-part to execute its antimicrobial activity. It can be speculated that MHBD2 is 
released from YebFMHBD2 in the human gut by the activity of trypsin as was shown 
for the proteolytic activation of the inactive proHD5. Trypsin cleaves after arginine 
and lysine residues and two arginine residues are the last two amino acid residues of 
the YebF-part in YebFMHBD2. 
Zhang and colleagues also found that by using YebF, e. g. as YebF-hIL2 
(human interleukin-2, 15 kDa and very hydrophobic), YebF-α-amylase (α-amylase, 
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48 kDa and hydrophilic) and YebF-alkaline phosphatase (94 kDa), YebF could carry 
these fusion proteins in their active states out of the producing bacterial cell and into 
the medium (Zhang et al. 2006).  
 They compared the simultaneous release of YebF-amylase and alkaline 
phosphatase, a well-defined periplasmic enzyme, from cells hosting pYebF-AmyH6. 
As alkaline phosphatase is induced by phosphatate starvation, it is poorly expressed 
in E. coli grown in rich medium containing inorganic phosphate salts. This study 
showed that 42.6 % of YebF-α-amylase was secreted to the medium compared to 
only 5.6 % of alkaline phosphatase (Zhang et al. 2006). Moreover, activity assays for 
the YebF-hIL-2 fusion protein based on the growth of cytotoxic T-lymphocyte line 
(CTLL)-2 in vitro showed the secreted protein in the medium to be active (43,800 
units of hIL-2/ml) (Zhang et al. 2006). 
These data are in agreement with our results that YebF has the ability to carry 
proteins of varying size and hydrophobicity/hydrophilicity from the cytoplasm of         
E. coli cells into the medium where the fusion protein shows the activity of the 
passenger protein.  
 
5.5.  Concluding remarks  
This study showed the successful construction of recombinant strains of the 
probiotic E. coli Nissle 1917 which not only were able to produce HD5 and HBD2 
defensin proteins but also produced antimicrobially active mature HBD2. Furthermore, 
a microcin-negative EcN mutant harboring plasmid pEAS106 secreted a fusion 
protein consisting of YebF and the mature part of HBD2 into the culture medium, and 
the secreted fusion protein even showed growth inhibition of E. coli, Salmonella and 
Listeria monocytogenes.  
In contrast to earlier reports about defensin production in E. coli K-12 strains 
(Huang et al., 2006; Pazgier and Lubkowski, 2006; Xu et al., 2006), this study reports 
for the first time the production of active HBD2 defensin in a probiotic E. coli strain 
(Nissle 1917), which is licensed as a drug for the treatment of patients suffering from 
e.g. diarrhea or ulcerative colitis. This probiotic strain is a good transient colonizer of 
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the human gut as opposed to E. coli K-12 strains which are not able to survive in the 
human digestive tract. Furthermore, to our knowledge, this is also the first study 
showing not just production but also secretion of mature HBD2 by an E. coli strain 
which showed activity against pathogenic Salmonella and Listeria strains. 
These constructs and the results achieved with them laid the foundation for 
the development of EcN as a delivery vehicle for defensins to patients suffering from 
a deficiency of such antimicrobial peptides. In Crohn´s disease, for example, the 
induction of defensin molecules, such as HBD2, is impaired, in part due to a genetic 
defect resulting in reduced amounts of HBD2 in the gut (Wehkamp and Stange 2006). 
Therefore, targeted delivery of HBD2 by a recombinant EcN-strain producing this 
defensin locally in the gut after oral administration could have a therapeutic effect in 
Crohn’s disease patients.  
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Supplementary results 
Table S1. Diameters of radial diffusion assays for antimicrobial activity tests of HisMHBD2 against      
E. coli K-12 MG1655. 
Protein 
samples 
Diameters (mm) 
Negative 
control, 
EcN100 a 
5 5 5 
EcN102 b 8 8 8 
commercial 
HBD2 c 
13 11 11 
 
a negative control (EcN100), 4 µg of fraction 0.03 eluted from Ni-column 
b
 eluted proteins including HisMHBD2 (EcN102), 4 µg of fraction 0.03 eluted from Ni-column 
c
 positive control, commercial HBD2, 1 µg  
 
Table S2. Diameters of radial diffusion assays for antimicrobial activity tests of HisMHBD2 against 
Salmonella enterica serovar Typhimurium SL1344. 
Protein 
samples 
Diameters (mm) 
Negative 
control, 
EcN100 a 
5 5 5 
EcN102 b 8 7 10 
commercial 
HBD2 c 
13 7 7 
 
a negative control (EcN100), 4 µg of fraction 0.03 eluted from Ni-column 
b
 eluted proteins including HisMHBD2 (EcN102), 4 µg of fraction 0.03 eluted from Ni-column 
c
 positive control, commercial HBD2, 1 µg  
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Table S3. Diameters of radial diffusion assays for antimicrobial activity tests of HisMHBD2 against 
Listeria monocytogenes EGD. 
Protein 
samples 
Diameters (mm) 
Negative 
control, 
EcN100 a 
5 5 5 
EcN102 b 6 7 7 
commercial 
HBD2 c 
10 9 8 
 
a negative control (EcN100), 4 µg of fraction 0.03 eluted from Ni-column 
b
 eluted proteins including HisMHBD2 (EcN102), 4 µg of fraction 0.03 eluted from Ni-column 
c
 positive control, commercial HBD2, 1 µg  
 
Table S4. Diameters of radial diffusion assays for antimicrobial activity tests of YebFMHBD2 against  
E. coli K-12 MG1655. 
Protein 
samples 
Diameters (mm) 
Negative 
control, 
SK22D105 d 
5 5 5 
SK22D106 e 12 13 13 
commercial 
HBD2 f 
13 10 10 
 
d negative control, proteins in the cell free supernatant after centrifugation and filtration from 
SK22D105, 4 µg 
e
 proteins in the cell free supernatant including YebFMHBD2 after centrifugation and filtration from 
SK22D106, 4 µg 
f
 positive control, commercial HBD2, 1 µg  
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Table S5. Diameters of radial diffusion assays for antimicrobial activity tests of YebFMHBD2 against 
Salmonella enterica serovar Typhimurium SL1344. 
Protein 
samples 
Diameters (mm) 
Negative 
control, 
SK22D105 d 
5 5 5 
SK22D106 e 13 8 8 
commercial 
HBD2 f 
12 8 7 
 
d negative control, proteins in the cell free supernatant after centrifugation and filtration from 
SK22D105, 4 µg 
e
 proteins in the cell free supernatant including YebFMHBD2 after centrifugation and filtration from 
SK22D106, 4 µg 
f
 positive control, commercial HBD2, 1 µg  
 
Table S6. Diameters of radial diffusion assays for antimicrobial activity tests of YebFMHBD2 against 
Listeria monocytogenes EGD. 
Protein 
samples 
Diameters (mm) 
Negative 
control, 
SK22D105 d 
5 5 5 
SK22D106 e 13 14 12 
commercial 
HBD2 f 
10 9 8 
 
d negative control, proteins in the cell free supernatant after centrifugation and filtration from 
SK22D105, 4 µg 
e
 proteins in the cell free supernatant including YebFMHBD2 after centrifugation and filtration from 
SK22D106, 4 µg 
f
 positive control, commercial HBD2, 1 µg  
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Table S7.  Bacterial cfu/ml of samples after incutabion at 37 °C for 4 h for antimicrobial test in liquid 
culture against E. coli K-12 MG1655.  
Protein 
samples 
(2.5 µl) 
Bacterial numbers (cfu/ml) 
SK22D105 
before 
incubation g 
6.20x106 6.10x106 1.96x107 2.36x107 3.14x107 3.12x107 
SK22D105 
after 
incubation g 
1.38x107 1.76x107 7.40x107 7.30x107 4.70x107 4.90x107 
SK22D106 
before 
incubation h 
7.90x106 4.70x106 1.14x107 1.14x107 2.83x107 2.38x107 
SK22D106 
after 
incubation h 
3.60x106 3.70x106 1.55x107 1.65x107 2.10x107 2.40x107 
 
g
 SK22D105 contained secreted proteins from SK22D105 and bacteria in 10 mM sodium phosphate 
buffer, pH 7.4, and 1 % TSB medium. 
h
 SK22D106 contained secreted proteins from SK22D106 and bacteria in 10 mM sodium phosphate 
buffer, pH 7.4, and 1 % TSB medium. 
 
Table S8.  Bacterial cfu/ml of samples after incutabion at 37 °C for 4 h for antimicrobial test in liquid 
culture against Listeria monocytogenes EGD.  
Protein 
samples 
Bacterial numbers (cfu/ml) 
Negative 
control  
before 
incubation i 
8.27x107 7.19x107 2.19x107 5.80x107 5.20x107 4.41x107 
Negative 
control after 
incubation i 
7.50x107 7.10x107 5.00x107 4.00x107 5.04x107 5.55x107 
SK22D105 
5µl before 
incubation g 
8.14x107 6.86x107 5.52x107 2.83x107 5.43x107 5.30x107 
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SK22D105 
5µl after 
incubation g 
7.00x107 1.17x108 4.70x107 1.90x107 5.59x107 5.19x107 
SK22D106 
5µl before 
incubation h 
5.66x107 6.54x107 4.26x107 4.45x107 3.59x107 5.17x107 
SK22D106 
5µl after 
incubation h 
7.40x107 8.30x107 3.30x106 1.66x107 4.70x107 4.80x107 
 
i
 Negative control contained bacteria in 10 mM sodium phosphate buffer, pH 7.4, and 1 % TSB 
medium without any proteins. 
g
 SK22D105 contained secreted proteins from SK22D105 and bacteria in 10 mM sodium phosphate 
buffer, pH 7.4, and 1 % TSB medium. 
h
 SK22D106 contained secreted proteins from SK22D106 and bacteria in 10 mM sodium phosphate 
buffer, pH 7.4, and 1 % TSB medium. 
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Abbreviations 
α                                 alpha 
A                                 alanine 
ApR                            ampicillin resistance 
 β                                beta 
 bp                              base pairs 
C                                cysteine 
cDNA                         complementary DNA  
CFU                           colony forming unit 
D                                aspartic acid 
Da                              Dalton 
dH2O                          destilled H2O    
∆                                Delta, difference operator 
DNA                           desoxyribonucleic acid 
dNTP                          2'-desoxyribonuclesid-5'-triphosphate  
ε                                 epsilon 
E                                glutamic acid 
EcN                            Escherichia coli strain Nissle 1917 
EcNc                          EcN cured from both cryptic plasmids 
e.g.                             exempi gratia 
EDTA                         ethylendiamintetraacetate 
et al.                           et altera     
EtOH                          ethanol    
g                                 gram 
G                                glycine 
H                                 histidine 
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HBD2                          human beta defensin 2 
HD5                            human alpha defensin 5 
hrs                              hours  
I                                  isoleucine 
IPTG                           Isopropyl-β-D-thogalactopyranosid 
K                                 lysine 
kb                                kilo bases  
Km                              kanamycin 
µ                                 micro 
m                                milli 
M                                methionine 
M                                molar 
MBP, MalE                 Maltose Binding Protein 
min                             minute   
N                                asparagine  
OD600                          optical density at 600nm 
P                                 proline 
PCR                            polymerase chain reaction 
Q                                 glutamine 
R                                 arginine 
RNA                            ribonuclease 
S                                 serine 
SDS-PAGE                 sodium dedecyl sulfate-polyacrylamide gel electrophoresis 
T                                 threonine 
TAE                            Tris-acetate-EDTA 
TBS                            Tris-buffered saline 
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TCA                            trichloroacetic acid 
TcR                             tetracycline resistance 
TEMED                      N,N,N', N'-tatramethyldiamin 
Tris                            Trishydroxylmethylaminomethan 
TLR                           Toll-like receptor     
V                               valine 
V                               Volt  
Y                               tyrosine 
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Physical maps of expression plasmids 
 
Fig. S1. Physical map of pGEM-T Easy vector (3015 bp) which is the convenient system for the 
cloning of PCR products with single 3'-T overhangs (Promega, USA). 
 
 
Fig. S2. Schematic representation of expression vector, pMUT1-Tc (4624 bp) mediating tetracycline 
resistance is a derivate of pMUT1, one of two very stable cryptic plasmids of EcN. 
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Fig. S3. Physical maps of the expression vectors (A) pCON3-86B (3997 bp), (B) pCON7-71(6025 bp) 
and (C) pCON7-74 (4874 bp) indicating unique restriction sites and showing relevant features 
(Anthony et al. 2004). 
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Fig. S4. Plasmid maps of expression vectors pT7-3 (2423 bp) and pT7-4 (2388 bp) which are 
expression vector system into which genes under the control of the T7-RNA-polymerase specific 
promoter phi10 can be cloned (Tabor and Richardson 1985). 
 
 
Fig. S5. Plasmid map of expression vector, pET-28a(+) (5369 bp) which encodes two His tags and 
allows expression of genes under the control of the T7 promoter (Novagen, USA). 
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Sequences 
nHBD2-gene (EMBL HE583189)  
atgcgtgttctgtatctgctgttctctttcctgttcatcttcctgatgccgctgccgggtgtgtttggtg 
gcattggtgatccggtgacctgcctgaaaagcggtgccatctgtcatccggtgttttgtccgcgtcgtta 
taaacagattggtacctgcggtctgccgggcaccaaatgctgtaaaaaaccgtaatga 
 
nHD5-gene (EMBL HE583188) 
atgcgtaccattgccattctggccgccattctgctggtggccctgcaggcccaggccgaaagcctgcagg 
aacgtgccgatgaagccaccacccagaaacagagcggtgaagataatcaggatctggccattagctttgc 
cggtaatggtctgagcgccctgcgtaccagcggtagccaggcccgtgccacctgctattgccgtaccggt 
cgttgcgccacccgtgaaagcctgagcggtgtgtgcgaaattagcggtcgtctgtatcgtctgtgctgcc 
gttaatga
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